



INTELLECTUAL
PROPERTY OFFICE
BRUNEI DARUSSALAM

31 October 2022

NO. 010/2022



PATENT JOURNAL

Brunei Darussalam Intellectual Property Office (BrulPO)

The Law Building, Ground Floor

Jalan Raja Isteri Pengiran Anak Saleha

Bandar Seri Begawan BA1910

Negara Brunei Darussalam

Tel: +673 2244873/4/5/6 Ext 102

Email: enquiries@bruipo.gov.bn

Brunei Darussalam Intellectual Property Office (BrulPO) © 2013. All rights reserved. Modification or reproduction of this Journal without the permission of BrulPO is prohibited.





CONTENTS

General Information	3
Operating Hours	3
Submission of Application	3
Enquiries	3
Patents Legislation	4
Forms and Fees	4
INID Codes	5
First Schedule – Fees	7
Second Schedule – Forms	15
Third Schedule – Scale of Cost Part 1 – Basic Costs	19
Part II – Additional Cost	20
Fourth Schedule – Micro-Organisms	21
Fifth Schedule – Remuneration of Scientific Advisers	27
New Patent Applications Filed	34
Patent Renewal Application	73
Patent Granted	125
Patent Recordal of Assignment	132



General Information

The Brunei Darussalam Intellectual Property Office (BruIPO) is an Office under the Attorney General's Chamber and its premises with effect from the 1 April, 2019 and is situated at the following address:

Brunei Darussalam Intellectual Property Office (BruIPO)
Attorney General's Chamber
The Law Building,
Jalan Raja Isteri Pengiran Anak Hajah Saleha,
Bandar Seri Begawan BA1910
Brunei Darussalam
Tel: +673 2225919

Opening Hours

With effect from 1 January, 2020, the Brunei Intellectual Property Office (BruIPO) counter will operate as follows:

Monday to Thursday	: 8.00am to 12.00pm 2.00pm to 3.00pm
Saturday	: 8.00am to 11.00am
Friday and Sunday	: CLOSED

Submission of Applications

1. All applications for the registration of patents must be lodged with the Registrar of Patents at the Brunei Darussalam Intellectual Property Office (BruIPO).
2. Submission of applications via fax is acceptable provided the documents transmitted are clear and legible (in particular, representations). For applications that require the payment of a fee, actual lodgement of the prescribed fee is required before such applications can be processed.

Enquiries

1. For enquiries relating to any information in this Journal, kindly contact the Office at telephone numbers +673 2225919. Hard copies of the Journal can be purchased upon request from the Office at a cost of B\$10.00 per copy.
2. The website of the Brunei Darussalam Intellectual Property Office (BruIPO) is <http://www.bruipo.gov.bn>.
3. All Patent-related enquiries via email can be submitted to enquiries@bruipo.gov.bn



Patents Legislation

1. The legislation governing the registration of Patent in Brunei Darussalam is the Patents Order 2011, while the subsidiary legislation is the Patents Rule, 2012.

2. The hard copies of the legislation can be purchased from: Print Plus Sdn Bhd Prime Minister's Office Jalan Airport Lama Bandar Seri Begawan BB3510 Brunei Darussalam Tel: 238 2541

3. The soft copies of the legislation can be obtained from www.bruipo.gov.bn

Forms and Fees

1. For any proceedings before the Registry, the prescribed form to be used and the accompanying fee payable shall be in accordance with the First and Second Schedule of the Patents Rule, 2012.

2. Payment by cheque should be made out to 'THE GOVERNMENT OF BRUNEI DARUSSALAM'.

Restrictions on Applications Abroad by Residents of Brunei Darussalam

1. Local applicants intending to file a patent abroad must first obtain the Registrar's written authority as prescribed under section 33(1) of the Patents Order, 2011.

2. Failure to observe this requirement is an offence under section 33(1)(b)(3) of the Order.

Transitional Applications

1. Transitional applications under Section 115 shall be lodged with the Registrar of Patents in the following manner:
 - Request to the Registrar of Patents for re-registration of a Singapore, Malaysia or United Kingdom/European patent;
 - Lodgement of Patent Form PF46;
 - Certified true copy of the grant of patent in the relevant country;
 - Prescribed fee of B\$250.00; and
 - Any other supporting documents that the Registrar deems necessary.

2. The filing of a Power of Attorney accompanying a request for re-registration is no longer a requirement with effect from 1 January 2012.



3. Any renewal due for patents registered under the repealed Inventions Act (Cap 72) on or after 1 January 2012 shall be made in accordance with Section 54 on Patents Form PF20. Applicants must furnish supporting documents proving the validity of the patents which are due for renewal.

4. Search on the Register of patents (re-registrations) can be conducted at the Office by completing a Search Form PF30 and the payment of a search fee of \$6.50 per hour.



'INID' NUMBERS IN USE ON BRUNEI PATENT DOCUMENTS

'INID' is an acronym for Internationally agreed Numbers for the Identification of Data'

(10) Document identification

- (11) Number of the document
- (12) Plain language designation of the kind of document
- (19) WIPO country code, or other identification, of the country publishing the document.

(20) Document filing data

- (21) Number(s) assigned to the application(s)
- (22) Date(s) of filing application(s)
- (23) Other date(s) of filing, including exhibition filing date and date of filing complete specification following provisional specification.
- (24) Date from which industrial property rights may have effect.

(30) Priority data

- (31) Number(s) assigned to priority application(s).
- (32) Date(s) of filing priority application(s).
- (33) Country (countries) in which the priority application(s) was (were) filed.

(40) Date(s) of making available to the public

- (43) Date of publication by printing or similar process of unexamined document, on which no grant has taken place on or before the said date.
- (44) Date of publication by printing or similar process of an examined document, on which no grant has taken place on or before the said date.
- (45) Date of publication by printing or similar process of a document, on which grant has taken place on or before the said date.
- (47) Date of making a granted patent available to the public by viewing, or copying on request

(50) Technical information

- (51) International Patent Classification
- (52) Domestic or national classification
- (54) Title of invention
- (56) List of prior art documents, if separate from descriptive text.
- (57) Abstract or claim.

(60) Reference(s) to other legally related domestic document(s)

- (60) Related by cognate(s).
- (61) Related by addition(s).
- (62) Related by division(s).

(70) Identification of parties concerned with the document



- (70) Name(s) of nominated person
- (71) Name(s) of applicant(s).
- (72) Name(s) of inventor(s) if known to be such.
- (74) Name(s) of attorney(s) or agent(s).
- (75) Name(s) of inventor(s) who is (are) also applicant(s)

(80) Identification of data related to International Conventions other than the Paris Convention

- (86) PCT Application Number.
- (87) PCT Publication Number.

NOTE

- (1) The classification used is the International Patent Classification and is identified by the INID code (51). Further editions of the classification are identified as (51)2, (51)3, (51)4 and (51)5.
- (2) INID code 74 provides for the name of patent attorney, or firm of attorneys, prosecuting an application.



PRACTICE NOTE 2012/01

PATENT RENEWALS

• RENEWAL OF PATENTS REGISTERED UNDER SECTION 115 OF THE PATENTS ORDER

1. For Section 115 applications, the following original documents need to be signed and submitted to the Registry of Patents:

- (a) PF20;
- (b) PF46 (for the first instance of renewal payment if that agent is not previously appointed);
- (c) evidence of the original patent not having been revoked, and
- (d) a cheque drawn on a Brunei bank account including the correct fee for both the PF20 and PF46. Cheques must be made payable to 'THE GOVERNMENT OF BRUNEI DARUSSALAM'.

2. PF20

The notes at the top of the form and applicable provisions in the Patents Order and Patent Rules should be followed strictly. Additional formatting guidelines are as follows:

Section 2: Brunei registration number in format RP/XX/YYYY for pre 2012 cases, and RE YYYY/XXXX for 2012 onwards.

Section 3: Original Patent number in the format UK: GBXXXXXXX or EPXXXXXXX; MY: MY-XXXXXX-A; and SG: XXXXX.

Section 4: This should match the current details on the Brunei Register (rather than the original patent register details).

Section 5: Agents attending to the renewal on behalf of the proprietor should leave Section 5 blank and instead fill in details in Section 7 and 8.

Section 6: The renewal deadline is calculated from the date of filing for all UK, MY and SG original cases.

3. PF46

Section 6: Most commonly the appointment is for renewal matters only, so the "for renewals only" box should be checked, assuming the agent has not been previously appointed.

4. PF21

Extension fees will become payable for renewals as of 1 January 2013.

5. Certification of original patent

Evidence must be provided that the original patent must not be "revoked" as of the date of the renewal being paid. Please note it does not matter if the original patent has "lapsed" or "ceased". Evidence can be in the form of a certified true copy of the applicable online register printed on the day of filing or a



statutory declaration to the same effect. The online register of the original patent can be printed and certified as a true copy by the authorised agent for the renewal using a suitable chop and signature.

- **EXPIRY OF PATENT AT THE END OF THE TERM OF THE PATENT**

6. Agents are reminded that under Section 115(4)(a), the term of a Section 115 patent is 20 years from the date of filing of the original (UK/MY/SG) patent; subject to Section 35 and 36. It does not make any difference which country the original patent is from.

AMENDMENT OF RULE 92 OF S 19/2012

Rule 92 of the Patent Rules, 2012, is amended by repealing sub-rule (1) and by substituting the following new sub-rule therefor –

“(1) Subject to this rule, in relation to an international application for a patent (Brunei Darussalam) which is, under section 82, to be treated as an application for a patent under the Order, the prescribed period for the purpose of section 83(3) and (5) shall be, in a case where Brunei Darussalam has been designated and/or elected in accordance with the Patent Co-operation Treaty, 30 months from the relevant date.”.

AMENDMENTS AND CORRECTIONS

- **AMENDMENT OF SPECIFICATION (RULES 51) OR CORRECTION OF ERROR IN SPECIFICATION (RULE 64)**


1. Unless required by the Registry under rules 51, an application for amendment of specification or a request for correction of an error in proposed amendment/correction incorporated; only a copy of the specification with the amendment/ correction indicated clearly therein is required. If a copy of the specification with the proposed amendment/correction incorporated is nonetheless filed, please be informed that the Registry will not review that document or consider it in any proceedings before the Registry.
2. The registry would also like to point out the replacement sheets with clear markings will reduce the need for clarification or further correspondences and hence will help expedite the processing of such requests.

- **AMENDMENTS/CORRECTIONS TO SPECIFICATION AND ABSTRACT**


1. Amendments/corrections to patent specifications and abstracts are to be clearly marked and completed by striking through text/figure etc. to be replaced, and by underlining replacement text/figure etc.
2. The following 3 examples reflect 3 possible alternative ways to which the changes could be represented. Example 4 reflects a situation where Patents Form 19 is filed.



Example 1: Page 10 of 19 sheets (Specification) is amended




Example 2: Page 10 of 19 sheets (Specification) is amended






Example 3: Page 10 of 19 sheets (Specification) is amended



This vertical line indicates the matter replacing the whole of page 10. To facilitate the document reproduction process however, the line should be placed about 0.5 cm to 1cm away from the 2.5 cm margin of each sheet.

Example 4: Page 10 of 19 sheets (Specification) is amended





- **COMMONLY MADE MISTAKES WHEN FILING PATENTS FORM 17**

The following are some of the commonly made mistakes in relation to making a request for amendments –

- Replacement sheets for amendments are not filed with Patents Form 17. –
- There is no marked up copy enclosed with Patents Form 17. –
- Patents Form 17 is filed without any replacement sheet. -
- Amendments to be made given on Patents Form 17 are different from the replacement sheets.

REGISTRATION UNDER SECTION 115

The following applications were processed through the Registry of Patents under section 115 of the Patents Order, 2011. Application numbers beginning with 'RP' are applications which were filed under the repealed Inventions Act (Cap 72) and were pending on 1 January 2012. Application numbers beginning with 'RE' are new re-registration applications filed after the implementation of the new Patents Order, 2011.

Date of filing:	17 February, 2020
Application No.:	RE/R/2020/0001
Patent No.:	EP2580236 B1 and US352461 P
Date of Grant:	8 June, 2011
Applicant (s)/Proprietor(s):	ASTRAZENECA AB and PIERIS PHARMACEUTICALS GMBH
Title:	TEAR LIPOCALIN MUTEINS BINDING IL-4 R ALPHA



FIRST SCHEDULE

FEES PAYABLE

<u>Matter</u>	<u>Fee</u>	<u>Corresponding Form(s)</u>
1. On filing a request for the grant of a patent	\$160.00	1
2. On reference under section 20(1) or 48(1)	\$450.00	2
3. On filing a counter-statement in each of the following cases –	\$40.00	3
(a) Opposing the making of an order under section 20 or 48		
(b) Opposing a request under section 22		
(c) In respect of a reference under section 23(5)		
(d) Opposing an application under section 24		
(e) In answer to a notice of opposition under section 38		
(f) In answer to a notice of opposition under section 41		
(g) In respect of a reference under section 49(5)		
(h) In respect of an application under section 55(3)		
(i) In answer to a notice of opposition under section 56(7)		
(j) In respect of a reference under section 65(3)		
(k) On contesting an application under section 76 for declaration of non- infringement		
(l) On contesting an application under section 77 for revocation of a patent		
(m) In answer to a notice of opposition under section 104(2) to the correction of an error, clerical error or mistake		
4. On application under section 20(5) or 48(3) for authorization by Registrar	\$50.00	4
5. On request for directions under section 22	\$450.00	5

6. On reference under section 23(5) or 49(5) to determine the question of licence	\$450.00	6
7. On application to the Registrar under section 24(1) 450 7 and/or 24(3)	\$450.00	7
8. On filing a statement of inventorship and of right to the grant of a patent	-	8
9. On request for early publication under section 27(2)	\$50.00	9
10. On filing a notice of withdrawal of an application for a patent under section 27(1)	-	10
11. On filing a request for a search report or a supplementary search report	\$1750.00	11
12. On filing a request for a search and examination report	\$2600.00	12
13. On furnishing information referred to in rule 46(1)	-	14
14. On filing a notice of intention to rely on an international preliminary report on patentability	-	15
15. On filing a request for an examination report	\$1100.00	16
16. On request to amend application before grant	-	17
17. On filing a response to a written opinion under section 31 or 39	-	18
18. On request that a certificate of grant be issued –		19
(a) where the application for a patent has not more than 25 claims in the patent specification when rule 49(3) is complied with	\$200.00	
(b) where the application for a patent has more than 25 claims in the patent specification when rule 49(3) is complied with	\$200.00 plus \$20.00 for Each claim in excess of 25 claims	
19. On payment of renewal fee (not including payment of back renewal fees pursuant to restoration or cancellation of entry in the register that licences are available as of right)	-	20

(a) for each year in respect of the 5th, 6th or 7th year of the patent		
(b) for each year in respect of the 8th, 9th or 10th year of the patent	\$160.00	
(c) for each year in respect of the 11th, 12th or 13th year of the patent	\$270.00	
(d) for each year in respect of the 14th, 15th or 16th year of the patent	\$350.00	
(e) for each year in respect of the 17th, 18th or 19th year of the patent	\$450.00	
(f) for the 20th year of the patent	\$550.00	
(g) for each year after the 20th year of the patent	\$650.00	
	\$950.00	
20. On payment of an additional fee for renewal under section 35(3) –		21
(a) not exceeding one month	\$50.00	
(b) each succeeding month (but not exceeding 6 months)	\$100.00	
21. On application to amend specification after grant	\$100.00	22
22. On notice of opposition to amendment of specification after grant	\$480.00	23
23. On application for the restoration of a patent	\$500.00	24
24. On payment of additional fee on the application for the restoration of a patent	\$300.00	25
25. On filing an offer to surrender a patent	\$70.00	26
26. On notice of opposition to offer to surrender a patent	\$250.00	27
27. On application to register or give notice of a transaction, instrument or event affecting the rights in a patent or an application for a patent – for each patent or application for a patent affected by such transaction, instrument or event	\$70.00	29
28. On filing a request, in respect of one or more patents or applications for patents, for –	\$12.00	28
(a) each alteration or correction of name		



(b) each alteration or correction of address (not being an address for service)		
29. On filing a request, in respect of each patent or application for a patent, for –	\$12.00	28
(a) each alteration or correction of address for service		
(b) each correction of an error in the register or any connected document		
(c) each correction of an error of translation or transcript or clerical error or mistake in the specification of a patent, in an application for a patent or in any document filed in connection with a patent or such an application		
30. On request for the furnishing of or access to miscellaneous information –		30
(a) fee for inspecting each file or document relating to a patent or patent application	\$6.50	
(b) fee for furnishing each file or document	\$6.00	
(c) fee for photocopying each page or part thereof of any other document by the staff of the Registry	\$0.30	
(d) where the document is placed in the public search room –		
(i) fee for self-service photocopying of each page or part of the document using a stored-value card	\$0.15	
(ii) fee for photocopying of each page or part thereof by the staff of the Registry	\$0.30	
31. On request for certificate of the Registrar –		31
(a) by impressed stamp -		
(i) for the first 20 sheets	\$18.00	
(ii) for each additional sheet thereafter	\$0.30	
(b) sealed and attached to the documents -		
(i) for the first 20 sheets	\$30.00	

(ii) for each additional sheet thereafter	\$0.30	
(c) in respect of a priority document under rule 17.1(b) of the Regulations under the Patent Cooperation Treaty	\$50.00	
(d) in respect of a certified copy of the international application for a patent under rule 124	\$28.00	
32. On application for entry of order of court in the register	\$10.00	32
33. On application by proprietor for entry to be made in the register to the effect that licences under the patent are to be available as of right	\$70.00	33
34. On application for settlement of terms of licence of right	\$380.00	34
35. On application under section 56(1) or section 56(3) for cancellation of entry in the register	\$70.00	35
36. On notice of opposition to an application under section 56(1) or 56(3) for cancellation of entry in the register	\$90.00	36
37. On reference to the Registrar of a dispute as to infringement	\$280.00	37
38. On application for declaration of non- infringement	\$280.00	38
39. On application under section 77 for the revocation of a patent	\$500.00	40
40. On request for re-examination of a patent in response to the Registrar's direction	\$900.00	41
41. On request for re-examination of a patent in response to the Registrar's direction	\$160.00	42
42. On payment of prescribed fee and request for publication of translation	\$70.00	43
43. On application to Registrar for an international application for a patent (Brunei Darussalam) to be treated as an application under the Order	\$160.00	44
44. On request for the exercise of the discretionary powers of the Registrar	\$100.00	48

45. On declaration of authorisation where agent appointed or in substitution for another	\$10.00 for each patent or application for patent	46
46. On payment of the advertisement fee upon receipt of the Registrar's request under rule 97(4)	\$18.00	47
47. On notice of opposition to the correction of an error, clerical error or mistake	\$100.00	48
48. On request for information relating to a patent or an application for a patent	\$24.00	49
49. On request for extension of each time or period under rule 114(4) - for each month or part of a month for which the extension is sought	\$200.00	50
50. On request for extension of each time or period under rule 114(6)	\$200.00	52
51. On payment of additional fee for extension of each time or period under rule 114(9) – for each month, or part of a month, for which the extension is granted	\$200.00	53
52. On request for extension of periods under sections 51 29(7) and 30(1)(a) – (a) where the application is not an international application for a patent (Brunel Darussalam) that has entered the national phase in Brunei Darussalam under section 83(3)	\$1800.00	
(b) where the application is an international application for patent (Brunei Darussalam) that has entered the national phase in Brunei Darussalam under section 83(3)	Nil	
53. On payment of transmittal fee under rule 14 of the Regulations under the Patent Co-operation Treaty	\$150.00	54
54. On payment of fee under rule 123(6) in respect of a request under rule 26 bis.3(a) of the Regulations under the Patent Co-operation Treaty	\$250.00	-

55. On request for certificate authorising release of sample of micro-organism	\$15.00	55
56. On notice of intention to restrict availability of samples of micro-organisms to experts	\$15.00	56
57. On request for certificate authorising release of sample of micro-organism to an expert	\$15.00	57
58. On payment of renewal fee under section 55 or 56 –		58
(a) for each year in respect of the 5th, 6th or 7th year of the patent	\$80.00	
(b) for each year in respect of the 8th, 9th or 10th year of the patent	\$135.00	
(c) for each year in respect of the 11th, 12th or 13th year of the patent	\$175.00	
(d) for each year in respect of the 14th, 15th or 16th year of the patent	\$225.00	
(e) for each year in respect of the 17th, 18th or 19th year of the patent	\$275.00	
(f) for the 20th year of the patent	\$325.00	
(g) for each year after the 20th year of the patent	\$475.00	
59. On application to extend the term of a patent under section 36	\$950.00	59
60. On filing a request for a search and examination report 60 after grant under section 39 –		60
(a) where the Examiner is the Austrian Patent Office	\$2680.00	
(b) where the Examiner is the Danish Patent and Trademark Office	\$3100.00	
(c) where the Examiner is the Hungarian Patent Office	\$2680.00	
61. On filing one or more documents under section 26(7)(c) or (8) or 28(8)	-	61

62. On filing a declaration under rule 9(2) or a request under rule 9(3)	\$120.00	62
63. On filing a request under rule 10(2)	\$250.00	62
64. On filing any miscellaneous document or documents	-	99
65. For using the patent computer facilities in the public search room of the Registry		
(a) for every half hour or part thereof of log on 2 access using the patent search terminal	\$2.00	
(b) for each sheet of information printed	\$0.30	
66. Purchase of a copy of —		
(a) Patents Journal A	\$10.00	
(b) Patents Journal B	\$36.00	



SECOND SCHEDULE

DESCRIPTIONS OF FORMS

<u>No.</u>	<u>Description of Form</u>	<u>Corresponding Form No.</u>
1	Certificate of Grant	Certificate Form 1
2	Certificate of Extension of Patent Term	Certificate Form 2
3	Request for the Grant of a Patent under section 25	Patents Form 1
4	Reference under section 20(1) or 48(1)	Patents Form 2
5	Counter statement	Patents Form 3
6	Application under section 20(5) or 48(3) for Authorisation by the Registrar	Patents Form 4
7	Request for Directions under section 22	Patents Form 5
8	Reference under section 23(5) or 48(5) to Determine the Question of a Licence	Patents Form 6
9	Application to Registrar under section 24(1) and/or 24(3)	Patents Form 7
10	Statement of Inventorship and of Right to the Grant of a Patent under section 24	Patents Form 8
11	Request for Early Publication under section 27(2)	Patents Form 9
12	Withdrawal of an Application for a Patent under section 27(1)	Patents Form 10
13	Request for a Search Report or Supplementary Search Report	Patents Form 11
14	Request for a Search and Examination Report	Patents Form 12
15	Furnishing of Prescribed Details	Patents Form 13
16	Furnishing of Prescribed Information	Patents Form 14
17	Notice of Intention to Rely on International Preliminary Report on Patentability under section 29(2)(e)(ii)	Patents Form 15
18	Request for an Examination Report	Patents Form 16
19	Request to Amend Application before Grant under section 31(2)	Patents Form 17



20	Response to Written Opinion under section 31 or 39	Patents Form 18
21	Payment of Fee for Grant of a Patent under section 30	Patents Form 19
22	Payment of Renewal Fee under section 35(2) or 56(2)	Patents Form 20
23	Payment of Additional Fee under section 35(3)	Patents Form 21
24	Application to Amend Specification after Grant under section 38	Patents Form 22
25	Notice of Opposition to Amendment of Specification after Grant under section 38 or 80	Patents Form 23
26	Application for Restoration of a Patent under section 40	Patents Form 24
27	Additional Fee on the Application for Restoration of a Patent under section 40	Patents Form 25
28	Offer to Surrender a Patent under section 41(1)	Patents Form 26
29	Notice of Opposition to Offer to Surrender a Patent under section 41(2)	Patents Form 27
30	Request for Alteration of Name, Address or Address for Service, or Correction of an Error, Clerical Error or Mistake under section 104	Patents Form 28
31	Application to Register or to Give Notice of a Transaction, Instrument or Event Affecting the Rights in a Patent or an Application for a Patent under section 44	Patents Form 29
32	Request for Miscellaneous Information under section 43 or 105	Patents Form 30
33	Request for Certificate of the Registrar under section 46	Patents Form 31
34	Application for Entry of Order of Court in the Register under section 44	Patents Form 32
35	Application for Entry to be Made in the Register to the effect that Licences under the Patent are to be available as of Right under section 55(1)	Patents Form 33
36	Application for Settlement of Terms of a Licence of Right under section 55(3)	Patents Form 34
37	Application under section 56(1) or (3) for Cancellation of Entry in the Register	Patents Form 35
38	Notice of Opposition to an Application under section 56(1) or (3) for Cancellation of Entry in the Register	Patents Form 36



39	Reference to the Registrar of a Dispute as to Infringement under section 65(3)	Patents Form 37
40	Application for Declaration of Non-Infringement under section 76	Patents Form 38
41	Application for Information on Corresponding Applications for a Patent	Patents Form 39
42	Application for Revocation of a Patent under section 77	Patents Form 40
43	Request for Re-Examination of a Patent in Response to direction of the Registrar under section 77	Patents Form 41
44	Payment of Fee for Entry into National Phase under section 83(3)	Patents Form 42
45	Payment of Prescribed Fee and Request for Publication of Translation under section 83(7)	Patents Form 43
46	Application to the Registrar for an International Application to be Treated as an Application under section 82 of the Order	Patents Form 44
47	Request for the Exercise of the Registrar's Discretionary Powers under section 89	Patents Form 45
48	Declaration of Authorisation where an Agent is Appointed or where One Agent is Substituted for Another	Patents Form 46
49	Additional Fee for the Advertisement of Proposed Correction under section 104	Patents Form 47
50	Notice of Opposition to the Correction of an Error, Clerical Error or Mistake under section 104	Patents Form 48
51	Request for Information Relating to a Patent or an Application for a Patent under section 105	Patents Form 49
52	Request for Extension of Time or Period under rule 114(4)	Patents Form 50
53	Request for Extension of Periods under sections 29 (7) and 30(1)(a)	Patents Form 51
54	Request for Extension of Time or Period under rule 114(6)	Patents Form 52
55	Additional Fee for Extension of Time or Period under rule 114(9)	Patents Form 53



56	Payment of Transmittal Fee under rule 14 of the Regulations under the Patent Co-Operation Treaty	Patents Form 54
57	Request for Certificate Authorising Release of Sample of Micro-Organism	Patents Form 55
58	Notice of Intention to Restrict Availability of Samples of Micro-Organisms to Experts	Patents Form 56
59	Request for Certificate Authorising Release of Sample of Micro-Organisms to an Expert	Patents Form 57
60	Payment of Renewal Fee pursuant to section 55(3)(d)	Patents Form 58
61	Request for an Extension of the Term of a Patent under section 36	Patents Form 59
62	Request for Search and Examination after Grant under section 39	Patents Form 60
63	Filing of Documents under section 26(7)(c) or (8) or 28(8)	Patents Form 61
64	Declaration under rule 9(2) or Request under rule 9(3) or 10(2)	Patents Form 62
65	Filing of Miscellaneous Document or Documents	Patents Form 99



THIRD SCHEDULE

SCALE OF COSTS

PART I

BASIC COST

<i>Item</i>	<i>Matter</i>	<i>Amount</i>
1	Drawing and filing notice of opposition or application for revocation together with statement of case	\$200.00
2	Drawing and filing a counter-statement	\$150.00
3	Preparing and lodging evidence for a notice of opposition, an application for revocation or a counter-statement	\$200.00 - \$800.00
4	Perusing a notice of opposition, an application for revocation or a counter-statement (per folio)	\$2.00 per folio
5	Preparing for all interlocutory proceedings	\$25.00 - \$120.00
6	Attending all interlocutory proceedings	\$25.00 - \$50.00
7	Preparing for hearing	\$500.00 - \$1500.00
8	Attendance at hearing by patent agent without advocate or solicitor	\$100.00 per hour up to a maximum of \$450.00 per day
9	Attendance at hearing by patent agent with instructing advocate or solicitor	\$60.00 per hour up to a maximum of \$270.00 per day
10	Advocate or Solicitor fees	\$120.00 per hour up to a maximum of \$540.00 per day
11	Drawing bill of costs (per folio)	\$2.00 per folio
12	Attending taxation, and obtaining the Registrar's certificate or order	\$50.00 - \$120.00



PART II

ADDITIONAL COSTS

1. A person who has paid a fee prescribed in these Rules in relation to proceedings before the Registrar shall be paid the amount of the fee.
2. A person attending proceedings before the Registrar shall be paid –
 - (a) a reasonable amount for expenses incurred for transport between the usual place of residence of the person and the place that he attends for that purpose; and
 - (b) if the person is required to be absent overnight from his usual place of residence, a reasonable amount as allowances up to a daily maximum of \$250 for meals and accommodation.
3. A person who, because of his professional, scientific or other special skill or knowledge, is summoned to appear before the Registrar as a witness shall be paid –
 - (a) if the person is remunerated in his occupation by wages, salary or fees, an amount equal to the amount of wages, salary or fees not paid to the person because of his attendance before the Registrar for that purpose, but such amount should not exceed \$150 per day; or
 - (b) in any other case, an amount of not less than \$100 but not more than \$150 for each day on which he so attends.



FOURTH SCHEDULE

MICRO-ORGANISMS

Applications.

1. (1) The specification of an application for a patent, or of a patent, for an invention which requires for its performance the use of a micro-organism –

- (a) which is not available to the public at the date of filing of the application; and
- (b) which cannot be described in the specification in such a manner as to enable the invention to be performed by a person skilled in the art, shall, in relation to the micro-organism itself, be treated for the purposes of the Order as disclosing the invention in such a manner only if one of the conditions set out in subparagraph (2), is satisfied.

(2) The conditions referred to in sub-paragraph (1) are –

- (a) a condition that –
 - (i) not later than the date of filing of the application, a culture of the micro-organism has been deposited with any international depositary authority which is able to furnish a sample of the micro-organism; and
 - (ii) the name of the international depositary authority, the date when the culture was deposited and the accession number of the deposit are given in the specification of the application; and
- (b) a condition, in the case of an international application for a patent (Brunei Darussalam) which is treated, by virtue of section 85 as a patent under the Order, or, as the case may be, an application for a patent under the Order, that the corresponding provisions of the Implementing Regulations to the Patent Co-operation Treaty have been complied with, and where a new deposit is made under paragraph 4, a further condition that the applicant or proprietor makes a new deposit in accordance with that paragraph.

(3) Where the condition of sub-paragraph (2)(a)(ii) is not satisfied at the time the application for a patent is filed, it shall be satisfied –

- (a) within 16 months from –
 - (i) the declared priority date; or
 - (ii) the date of filing the application where there is no declared priority date;
- (b) where, on a request made by the applicant, the Registrar publishes the application before the end of the period prescribed for the purposes of section 27(1), before the



date of the request; or

- (c) where the Registrar sends notification to the applicant that, in accordance with section 105(4), he has received a request by any person for information and inspection of documents under subsection (1) of that section, before the end of one month after his sending to the applicant notification of his receipt of the request, whichever is the earliest.
- (4) The giving of the information specified in sub-paragraph (2)(a)(ii) shall constitute the unreserved and irrecoverable consent of the applicant to the international depositary authority with which a culture (including a deposit which is to be treated as having always been available by virtue of paragraph 4(2)) is from time to time deposited making the culture available on receipt of the Registrar's certificate authorising the release to the person who is named therein as a person to whom the culture may be made available and who makes a valid request therefor to the authority.

Availability of cultures.

- 2. (1) Subject to paragraph 3, a request that the Registrar certify a person as a person to whom an international depositary authority may furnish a sample of a micro-organism –
 - (a) before publication of the application for a patent, to a person who has made a request under section 105(1) in the circumstances mentioned in paragraph 1(3)(c); and
 - (b) at any later time, to any person, shall be made on Patents Form 55 together with the form provided for by the Regulations under the Budapest Treaty.
- (2) The Registrar shall send a copy of any form lodged with him under subparagraph (1) and of his certificate authorising the release of the sample –
 - (a) to the applicant for, or proprietor of, the patent;
 - (b) to the international depositary authority; and (c) to the person making the request.
- (3) A request under sub-paragraph (1) shall comprise, on the part of the person to whom the request relates, undertakings for the benefit of the applicant for, or proprietor of, the patent –
 - (a) not to make the culture, or any culture derived from it, available to any other person; and
 - (b) not to use the culture, or any culture derived from it, otherwise than for experimental purposes relating to the subject matter of the invention, and –
 - (i) subject to sub-paragraph (iii), both undertakings shall have effect during any period before the application for a patent has been withdrawn, has been treated as having been abandoned, has been refused or is treated as having been refused (including any further period allowed under rule 110, 120(1) or (6) but excluding,



where an application is reinstated under either of those rules, the period before it is reinstated);

- (ii) if a patent is granted on the application, the undertaking set out in sub-paragraph (a) shall also have effect during any period for which the patent is in force and during the period of 6 months referred to in section 35(3); and
- (iii) the undertaking set out in sub-paragraph (b) shall not have effect after the date of publication in the journal of a notice that the patent has been granted, and, in this sub-paragraph, references to a culture derived from a deposited culture of a microorganism are references to a culture so derived which exhibits those characteristics of the deposited culture essential for the performance of the invention.

(4) For the purpose of enabling any act specified in section 59 to be done in relation to the culture for the services of the Government, the undertakings specified in subparagraph (3) –

- (a) shall not be required from any Government department or person authorised in writing by a Government department for the purposes of this paragraph; and
- (b) shall not have effect in relation to any such person who has already given them.

(5) An undertaking given pursuant to sub-paragraph (3) may be varied by way of derogation by agreement between the applicant or proprietor and the person by whom it is given.

(6) Where, in respect of a patent to which the undertaking set out in sub-paragraph (3)(a) has effect –

- (a) an entry is made in the register under section 55 to the effect that licences are to be available as of right; or
- (b) a compulsory licence is granted under section 57, that undertaking shall not have effect to the extent necessary for effect to be given to any such licence.

Availability of cultures to experts.

3. (1) Subject to sub-paragraph (3), where, before the preparations for publication under section 27 of an application for a patent have been completed, the applicant gives notice to the Registrar on Patents Form 56 of his intention that a sample of the microorganism should be made available only to an expert, the provisions of this paragraph shall have effect.

(2) The Registrar –

- (a) shall, at the time of publication of the application under section 27, publish a notice in the journal that the provisions of this paragraph have effect; and
- (b) notwithstanding paragraph 2, shall not, until the patent is granted or the application has been withdrawn, has been treated as having been abandoned, has been refused or is



treated as having been refused, issue any certificate authorising release of a sample otherwise than under this paragraph.

(3) In the case of an international application for a patent (Brunei Darussalam), the applicant may, for the purpose set out in sub-paragraph (1), give notice in writing to the International Bureau under rule 13 bis 3 of the Regulations under the Patent Co-operation Treaty before the technical preparations for international publication of the application are complete of his intention that a sample of the micro-organism should be made available only to an expert and he shall be treated by the Registrar for the purposes of this paragraph as having complied with the conditions in sub-paragraph (1) and sub-paragraph (2)(a) shall not apply.

(4) Any person wishing to have a sample of the micro-organism made available ("the requester") –

(a) shall apply to the Registrar on Patents Form 57 together with the form provided for by the Regulations under the Patent Co-operation Treaty nominating the person ("the expert") to whom he wishes the sample to be made available; and

(b) shall at the same time file undertakings by the expert as set out in paragraph 2 (3) in accordance with the provisions of that paragraph.

(5) The Registrar shall send a copy of Patents Form 57 filed under sub-paragraph (4) to the applicant for the patent and shall specify the period within which the applicant may object, in accordance with sub-paragraph (6), to a sample of the micro-organism being available to the expert.

(6) Unless, within the period specified by the Registrar under sub-paragraph (5) (or within such longer period as the Registrar may, on application made to him within that period, allow), the applicant for the patent sends notice in writing to the Registrar that he objects to a sample of the micro-organism being made available to the expert and gives his reasons for his objection, the Registrar shall send a copy of any form lodged with him under sub-paragraph (4)(a) and of his certificate authorising the release of the sample –

(a) to the applicant for the patent;
(b) to the international depositary authority concerned;
(c) to the requester; and
(d) to the expert.

(7) Where, in accordance with sub-paragraph (6), the applicant for the patent sends notice to the Registrar of his objection to the issue of a certificate in favour of the expert, the Registrar –

(a) shall decide, having regard to the knowledge, experience and technical qualifications of the expert and to any other factors he considers relevant, whether to issue his certificate in favour of the expert; and

(b) if he decides to authorise the release of the sample to the expert, shall send to the persons



referred to in sub-paragraph (6) a copy of any form lodged with him under subparagraph (4)(a) and of his certificate authorising the release of the sample to the expert.

(8) Before making a decision in accordance with sub-paragraph (7), the Registrar shall afford the applicant and the requester the opportunity of being heard.

(9) If the Registrar decides under sub-paragraph (7) not to issue his certificate in favour of the expert, the requester may, by notice in writing to the Registrar and the applicant, nominate another person as the expert for the purposes of this paragraph; and the Registrar shall give such directions as he may think fit with regard to the subsequent procedure.

(10) Nothing in this paragraph shall affect the rights under section 58 of any Government department or of any person authorised in writing by a Government department.

New deposits.

4. (1) Where the international depositary authority with which a deposit or a new deposit of a culture has been made under this Schedule –

(a) notifies the applicant or proprietor that it –

(i) cannot satisfy a request made in accordance with paragraph 2(1) or 3(4); or

(ii) is not able lawfully, to satisfy such a request, for the culture to be made available;

(b) ceases temporarily or permanently to carry out the functions of an international depositary authority; or

(c) ceases for any reason to conduct its activities as an international depositary authority in an objective and impartial manner, subject to sub-paragraph (3), the applicant or proprietor may, unless the culture has been transferred to another international depositary authority which is able to make it available, make a new deposit of a culture of the micro-organism.

(2) For the purposes of paragraph 1 and this paragraph, the deposit shall be treated as always having been available if, within 3 months of the receipt of such notification or of the international depositary authority ceasing to perform the functions of an international depositary authority or to conduct its activities as such an authority in an objective and impartial manner, the applicant or proprietor –

(a) in a case where the deposit has not already been transferred, makes the new deposit;

(b) furnishes to the international depositary authority with which the new deposit is made a declaration that the culture so deposited is of the same microorganism as was the culture originally deposited; and



(c) requests amendment of the specification under section 31 or 38, as the case may be, so as to indicate the accession number of the transferred or new deposit and, where applicable, the name of the international depositary authority with which the deposit has been made.

(3) The new deposit referred to in sub-paragraph (1) –

(a) shall, subject to sub-paragraph (b), be made with the same international depositary authority as was the original deposit; or

(b) in the cases referred to in sub-paragraphs (1)(a)(ii), (b) and (c), shall be made with another international depositary authority which is able to satisfy the request.

Interpretation.

5. In this Schedule –

"Budapest Treaty" means the Treaty on the International Recognition of the Deposit of Microorganisms for the purposes of Patent Procedure done at Budapest in 1977; "depositary institution" means an institution which, at all relevant times –

(a) carries out the functions of receiving, accepting and storing microorganisms and the furnishing of samples thereof; and

(b) conducts its affairs in so far as they relate to the carrying out of those functions in an objective and impartial manner;

"international depositary authority" means a depositary institution which has acquired the status of international depositary authority as provided in Article 7 of the Budapest Treaty.



FIFTH SCHEDULE

REMUNERATION OF SCIENTIFIC ADVISERS

1. A person appointed as a scientific adviser to assist the Registrar in proceedings under the Order and who attends the proceedings before the Registrar shall be paid –
 - (a) a reasonable amount for expenses incurred for transport between his usual place of residence and the place where the proceedings take place; and
 - (b) if the scientific adviser is required to be absent overnight from his usual place of residence, a reasonable amount as allowance for meals and accommodation up to a daily maximum of \$250.
2. A person appointed as a scientific adviser to assist the Registrar in proceedings under the Order shall, apart from the expenses and allowances referred to in paragraph 1, be paid an amount of not less than \$650 but not more than \$2,000 for each day or part thereof for which he hears the case or works on the report pursuant to an inquiry referred to him under rule 119(1)(b).
3. A person appointed as a scientific adviser to sit with the Registrar at the hearing of any proceedings may, apart from the expenses and allowances referred to in paragraph 1, be paid an amount not less than \$650 but not more than \$2,000 if he is subsequently not required to hear the proceedings with the Registrar.



**REGISTRAR OF PATENT
BRUNEI DARUSSALAM**

PATENTS RULES [S 11/2013]

NEW PATENT APPLICATION

[21] BN/N/2022/0074 [22] 01/06/2022

[54] Dosing Of A Bruton's Tyrosine Kinase Inhibitor

[71] LOXO ONCOLOGY, INC. c/o ELI LILLY AND COMPANY of Lilly Corporate Center Indianapolis, Indiana 46285 United States of America

[72] 1. BRANDHUBER, BARBARA JEAN
2. KU, NORA CHIEN YEE
3. NANDA, NISHA
4. SMITH, STEVEN AUGUST
5. TSAI, DONALD

[74] Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD c/o AIP Law of Unit Nos. 404A-410A 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam

[31][32][33]
No. 62/944,674 Date: 06 December 2019 Country: United States of America
No. 63/077,996 Date: 14 September 2020 Country: United States of America
No. 63/109,698 Date: 04 November 2020 Country: United States of America

[86] PCT/US2020/063089

[87] WO/2021/113497

[51] A61K 31/415, A61P 35/00, A61P 35/02

[57] The present invention provides a method of administering doses of the BTK inhibitor, (S)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropane-2-yl)-1H-pyrazole-4-carboxamide or a pharmaceutically acceptable salt thereof for use in treating conditions such as cancer and autoimmune diseases.

[21] BN/N/2022/0075 [22] 01/06/2022

[54] Pre-Targeting Imaging Agents



[71] **ELI LILLY AND COMPANY** of Lilly Corporate Center Indianapolis, Indiana 46285 United States of America

[72] 1. CAGNOLINI, ALDO
2. XIONG, HUI

[74] **Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD** c/o AIP Law of Unit Nos. 404A-410A 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam

[31][32][33]

No. 62/946,218 Date: 10 December 2019 Country: United States of America

[86] PCT/US2020/063357

[87] WO/2021/118885

[51] A61K 51/04, A61K 101/02, C07D 257/08

[57] The present invention provides a novel compound of the formula: methods of making this compound, methods of using this compound for pretargeted imaging, and preparations of such formulations.



[21] BN/N/2022/0076 [22] 06/06/2022

[54] **Incretin Analogs And Uses Thereof**

[71] **ELI LILLY AND COMPANY** of Lilly Corporate Center Indianapolis, Indiana 46285 United States of America

[72] 1. ALSINA-FERNANDEZ, JORGE
2. COSKUN, TAMER
3. QU, HONGCHANG
4. ABRAHAM, MILATA MARY
5. WALLIS, JAMES LINCOLN

[74] **Messrs. AIP LAW** of Unit Nos. 404A-410A 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811 Brunei Darussalam

[31][32][33]



No. 62/949,661 Date: 18 December 2019 County: United States of America

[86] PCT/US2020/064512

[87] WO/2021/126695

[51] C07K 14/605, A61K 38/26

[57] Incretin analogs are provided that have activity at each of the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide- 1 (GLP-1) and glucagon (GCG) receptors. The incretin analogs have structural features resulting in balanced activity and extended duration of action at each of these receptors. Methods also are provided for treating diseases such as type 2 diabetes mellitus, dyslipidemia, metabolic syndrome, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and obesity.

[21] BN/N/2022/0077

[22] 06/06/2022

[54] Compliant Screen Shroud To Limit Expansion

[71] HALLIBURTON ENERGY SERVICES, INC. of 3000 N. Sam Houston Parkway E., Houston, Texas 77032-3219, United States Of America

[72] 1. GRECI, STEPHEN MICHAEL
2. FRIPP, MICHAEL LINLEY
3. GRANT, DAVID

[74] Messrs. HENRY GOH & CO SDN BHD c/o AIP Law of Unit Nos. 404A-410A 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam

[31][32][33]

No. 16/779,293 Date: 31 January 2020 Country: United States of America

[86] PCT/US2020/016272


[87] WO/2021/154305

[51] E21B 43/086

[57] Compliant wellbores screens may be arranged to radially expand in a wellbore. The screens include an outer shroud layer including a perforation pattern thereon arranged for limiting the degree to which the screens are expand. The perforation patterns may permit the screens to be expanded to a predetermined limit by imparting a stable or relatively low expansion force. Once the predetermined limit is reached, the



outer shrouds may require a sharp increase in the expansion force for further expansion. The sharp increase will prevent over-expansion of the screens, particularly where precise control over an expansion force imparted to expand the screens proves difficult. The perforation pattern may include arc- shaped perforations formed in sheet metal, spaces between braided metal strands, or many other arrangements



[21] BN/N/2022/0078 [22] 09/06/2022

[54] Kras G12c Inhibitors

[71] ELI LILY AND COMPANY of Lily Corporate Center, Indianapolis, Indiana 46285, United States of America

[72] 1. BOULET, SERGE LOUIS
2. FORTNER, KEVIN CHARLES
3. GUO, DEQI
4. HYMAN, DAVID MICHAEL
5. PENG, SHENG-BIN
6. SI, CHONG

[74] Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD c/o AIP Law of Unit Nos. 404A-410A 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam


[31][32][33]
No. 62/946,586 Date: 11 December 2019 Country: United States of America

[86] PCT/US2020/063272

[87] WO/2021/118877

[51] A61P 35/00, C07D 487/04, C07D 498/04, A61 31/553

[57] The present invention provides compounds of the formula: where R_1 , R_2 , R_3 , R_4 , R_5 , A , B , and Y are as described herein, pharmaceutically acceptable salts thereof, and methods of using these compounds and salts for treating patients for cancer.



[21] BN/N/2022/0079 [22] 11/06/2022

[54] Compound And Composition Serving As PDGF Receptor Kinase Inhibitor

[71] NIPPON SHINYAKU CO., LTD. of 14, Kisshoin Nishinoshio Monguchicho, Minami-ku, Kyoto-shi, Kyoto 6018550, Japan

[72] 1. ASADA, JUNSHI
2. HARUTA, YOSHINARI
3. YAKUSHIJI, HIROYUKI
4. TANAKA, TORU
5. KURAMOTO, KAZUYA
6. KOSUGI, KEIJI
7. FUCHIKAMI, CHIAKI

[74] Messrs. MARKS&CLERK SINGAPORE LLP c/o AIP Law of Unit Nos. 405A-410A
4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam

[31][32][33]
No. 2019-224959 Date: 13 December 2019 Country: Japan


[86] PCT/JP2020/046201

[87] WO/2021/117846

[51] A61P 9/00, A61P 9/10, A61P 9/12, A61P 9/14, A61P 11/00, A61P 11/06, A61P 11/08, A61P 27/02, A61P 35/00, A61P 35/02, A61P 43/00, C07D 401/04, C07D 405/04, C07D 409/04, C07D 471/04, C07D 495/04, C07D 513/04, A61P 17/00, C07D 213/54, C07D 213/61, C07D 213/73, C07D 213/81, C07D 215/12, C07D 263/34, C07D 487/04, C07D 498/04, C07D 239/14, C07D 239/74, C07D 277/56, C07D 241/12, C07D 241/20, A61K 31/421, A61K 31/426, A61K 31/429, A61K 31/4365, A61K 31/437, A61K 31/44, A61K 31/4402, A61K 31/4406, A61K 31/4418, A61K 31/4427, A61K 31/443, A61K 31/4433, A61K 31/4439, A61K 31/47, A61K 31/4965, A61K 31/5025, A61K 31/505, A61K 31/506,

A61K 31/517, A61K 31/519, A61K 31/5377, A61K 31/5383

[57] The purpose of the present invention is to provide a compound having an inhibitory activity against a PDGF receptor kinase. The present invention includes, for example, a compound represented by formula [1] or a pharmaceutically acceptable salt of the compound, or a solvate of the compound. The compound of the present invention has an inhibitory activity against a PDGF receptor kinase. Due to the inhibitory activity thereof against a PDGF receptor kinase, the compound of the present invention is useful as a therapeutic agent for respiratory diseases, cancer, smooth muscle proliferative diseases, vascular proliferative diseases, autoimmune/inflammatory diseases, metabolic diseases, vascular obstructive diseases and the like.



[21] BN/N/2022/0080 [22] 15/06/2022

[54] **Dual Interleukin-2 /Tnf Receptor Agonist For Use In Therapy**

[71] **AMGEN INC. of One Amgen Center Drive Thousand Oaks, California 91320-1799, United States of America**

[72] **1. CHAUDRHY, ASHUTOSH
2. OUYANG, WENJUN**

[74] **Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD c/o AIP Law of Unit Nos. 405A-410A 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam**

[31][32][33]
No. 62/949,380 Date: 17 December 2019 Country: United States of America

[86] **PCT/US2020/065734**

[87] **WO/2021/127262**


[51] **C07K 16/24, C07K 14/55, C07K 16/28**

[57] Provided herein are combinations of an IL-2 molecule or mutein and a TNFR agonist, and complexes comprising IL-2/TNFR agonist molecules, such as Fc-bound IL-2/TNFR agonist molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are methods of



making and using the compositions of the disclosure

FIG. 1



[21] BN/N/2022/0081 [22] 16/06/2022

[54] Synthetic Triterpenoids With Nitrogen-Based Substituents At C-17 And Methods Of Use Thereof

[71] REATA PHARMACEUTICALS, INC. of 2801 Gateway Drive, Suite 150, Irving, Texas 75063-2648, United States of America

[72] 1. BENDER, CHRISTOPHER, F
2. DO, HA
3. JIANG, XIN
4. SUN, HAIZHOU
5. VISNICK, MELEAN
6. JANSER, INGO
7. SIMONS, LLOYD, J.
8. SCHOSTAREZ, HEINRICH, J.

[74] Messrs. SPRUSON & FERGUSON PTE LTD c/o AIP Law of Unit Nos. 405A-410A 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam

[31][32][33]
No. 62/950,919 Date: 19 December 2019 Country: United States of America
No. 62/950,927 Date: 19 December 2019 Country: United States of America
No. 62/198,310 Date: 09 October 2020 Country: United States of America


[86] PCT/US2020/066073

[87] WO/2021/127480

[51] C07J 63/00, A61P 9/10, A61P 17/06, A61P 19/02, A61P 25/04, A61P 25/28, A61P 27/06, A61P 27/14, A61P 29/00, A61P 35/00, A61P 37/06, A61P 27/02, A61P 25/00, A61P 25/08, A61P 25/24, A61P 25/02, A61K 31/58, A61K 31/56



[57] In some aspects, the present disclosure provides compounds of the formula: (I) and (II), wherein the variables are defined herein. Also provided are pharmaceutical compositions thereof. In some aspects, the compounds and compositions provided herein may be used as antioxidant inflammation modulators. In some aspects, the present disclosure provides methods wherein the compounds and composition described herein are used for the treatment of diseases and disorders associated with inflammation and cancer.



[21] BN/N/2022/0082 [22] 22/06/2022

[54] Carboxy Derivatives With Antiinflammatory Properties

[71] SITRYX THERAPEUTICS LIMITED of 101 Bellhouse Building Magdalen Centre
The Oxford Science Park, Oxford Ox4 4ga United Kingdom

[72] 1. COOKE, MICHAEL LIAM
2. COUSIN, DAVID
3. FYFE, MATTHEW COLIN THOR
4. WAUGH, THOMAS MICHAEL
5. AHMED, SALEH
6. DE SIMONE, ALESSIO
7. TEOBALD, BARRY JOHN

[74] Messrs. AIP LAW of Unit Nos. 405A-410A 4th Floor, Wisma Jaya, Jalan Pemancha,
Bandar Seri Begawan BS8811, Brunei Darussalam

[31][32][33]
No. 19219531.1 Date: 23 December 2019 Country: European Patent Office
No. 20162545.6 Date: 11 March 2020 Country: European Patent Office
No. 20189623.0 Date: 05 October 2020 Country: European Patent Office
No. 20205768.3 Date: 04 November 2020 Country: European Patent Office

[86] PCT/GB2020/053357



[87] WO/2021/130492

[51] C07D 271/06, A61K 31/4245, A61P 19/02, A61P 29/00

[57] The invention relates to compounds of formula (I) and to their use in treating or



preventing an inflammatory disease or a disease associated with an undesirable immune response: (I) wherein, R^{A1} , R^{A2} , R^C and R^D are as defined herein.



[21] BN/N/2022/0083 [22] 23/06/2022

[54] **Completion Systems And Methods 5 To Perform Completion Operations**

[71] **HALLIBURTON ENERGY SERVICES, INC. of 3000 N. Sam Houston Pkwy E., Houston, Texas 77032-3219, United States Of America**

[72] **1. MACEK, MARK DOUGLAS
2. KAPPE, COLIN E.**

[74] **Messrs. AIP LAW of Unit Nos. 405A-410A 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam**

[31][32][33]
No. 16/776,298 Date: 29 January 2020 Country: United States of America

[86] PCT/US2020/017648


[87] WO/2021/154311

[51] E21B 43/26, E21B 33/12, E21B 34/10, E21B 34/00

[57] Completion systems and methods to perform completion operations are disclosed. A completion system includes a tubular having a wall that defines a flowbore. The completion system also includes a first port disposed in the wall and configured to provide fluid communication between the flowbore and the annular region, and a communication path disposed at least partially within the wall and configured to provide fluid communication with an annulus of a well outside of the zone. The completion system further includes a second port disposed in the wall and configured to provide fluid communication between the flowbore and the communication path, a first diverter seat disposed in the flowbore upstream of the second port and configured to receive a diverter flowing through the flowbore; and a second diverter seat disposed in



the flowbore uphole of the diverter seat and configurable to receive a second diverter flowing through the flowbore.



[21] BN/N/2022/0084

[22] 23/06/2022

[54] Completion Systems And Methods To Perform Completion Operations

[71] HALLIBURTON ENERGY SERVICES, INC. of 3000 N. Sam Houston Pkwy E., Houston, Texas 77032-3219, United States Of America

[72] 1. MACEK, MARK DOUGLAS
2. KAPPE, COLIN E.

[74] Messrs. AIP LAW of Unit Nos. 405A-410A 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam

[31][32][33]

No. 16/776,270 Date: 29 January 2020 Country: United States of America

[86] PCT/US2020/017650


[87] WO/2021/154312

[51] E21B 43/26, E21B 33/12, E21B 34/10, E21B 34/00

[57] Completion Systems and Methods to Perform Completion Operations are disclosed. A completion system includes a tubular having a wall that defines a flowbore within the tubular and extending into a zone of an annular region external to the tubular. The completion system also includes a first port disposed in the wall and configured to provide fluid communication between the flowbore and the annular region, and a



communication path disposed at least partially within the wall and configured to provide fluid communication with an annulus of a well outside of the zone. The completion system further includes a second port disposed in the wall and configured to provide fluid communication between the flowbore and the communication path, a cover disposed over the second port and configured to prevent fluid communication during a fracturing operation, and a diverter seat disposed in the flowbore of the tubular uphole of the second port.



[21] BN/N/2022/0085

[22] 04/07/2022

[54] Inhibitors Of Sarm1

[71] DISARM THERAPEUTICS, INC. of 1 Main Street, 11th Floor, Cambridge, Massachusetts 02142, United States of America

[72] 1. BENTLEY, JONATHAN
2. BOSANAC, TODD
3. BREARLEY, ANDREW SIMON
4. COOPER, SOPHIE CATHERINE
5. DEVRAJ, RAJESH
6. HUGHES, ROBERT OWEN
7. JARJES-PIKE, RICHARD ANDREW
8. MARLIN, FREDERIC JACQUES
9. PARROTT, SHELLEY ANNE
10. SILVA, DANIEL

[74] Messrs. SPRUSON & FERGUSON PTE LTD c/o AIP Law of Unit Nos. 405A-410A 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam

[31][32][33]



No. 62/958,178 Date: 07 January 2020 Country: United States of America
No. 63/065,736 Date: 14 August 2020 Country: United States of America

[86] PCT/US2021/012333

[87] WO/2021/142006

[51] C07D 401/04, C07D 401/14, C07D 405/04, C07D 409/14, C07D 413/14, C07D 417/04, C07D 471/04, C07D 491/04, A61P 25/00, A61K 31/4439

[57] The present disclosure provides compounds and methods useful for inhibiting SARM1 and/or treating and/or preventing axonal degeneration.

[21] BN/N/2022/0086 [22] 07/07/2022

[54] Self-Locking Threaded Connection Partially In Non-Locking Engagement

[71] VALLOUREC OIL AND GAS FRANCE of 54 rue Anatole France, 59620 Aulnoye-Aymeries, France
NIPPON STEEL CORPORATION of 6-1, Marunouchi 2-chome, Chiyoda-ku, Tokyo, 100-8071, Japan

[72] 1. OTT, WESLEY
2. GRANGER, SCOTT

[74] Messrs. HENRY GOH & CO SDN BHD c/o AIP Law of Unit Nos. 405A-410A 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam

[31][32][33]
No. 20153787.5 Date: 27 January 2020 Country: European Patent Office

[86] PCT/EP2021/051552


[87] WO/2021/151810

[51] E21B 17/042

[57] A self-locking threaded connection partially in a non locking engagement comprises a first and a second tubular component provided respectively with male and female threaded zone (3, 4) at their respective ends. First portions (11, 12) of the female threaded zones with varying thread width and root cooperate together along a self-locking tightening arrangement. A locking region (10) within the threaded connection is located in the middle of non locking portions (22, 23), and radially centered to the pipe body API tolerances in order to withstand high torque and seal performances.



Fig. 1



[21] BN/N/2022/0087

[22] 19/07/2022

[54] **Audio Information Transmission System, Method, Device, Corresponding Two-Wheeled Vehicle, And Helmet**

[71] **SHARKGULF TECHNOLOGY (QINGDAO) CO., LTD.** of Room 8206-1-4 (A), 2f Qiantongtuan Office Building, No. 44 Moscow Road, Qianwan Bonded Port Area, Qingdao Area, China (Shandong) Pilot Free Trade Zone, Qingdao, Shandong 266000, China

[72] 1. LIU, KE
2. HU, HUI

[74] Messrs. HENRY GOH & CO SDN BHD c/o AIP Law of Unit Nos. 405A-410A 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam

[31][32][33]

No. 202010057148.4 Date: 19 January 2020 Country: China

[86] PCT/CN2021/071003

[87] WO/2021/143631

[51] G10L 10/008, G06F 3/16, H04S 7/00

[57] Disclosed are an audio information transmission system, a method, a device, a corresponding two-wheeled vehicle, and a helmet. The system comprises a media control device and an audio switching device connected to the media control device. The audio switching device is connected to a mobile terminal and a helmet, and is used to receive first audio information sent by the mobile terminal and send the information to the media control device. The media control device is used to receive the first audio information and second audio information generated by a two-wheeled vehicle, and perform mixing to produce mixed audio information. The audio switching device sends the mixed audio information to the helmet. The present invention performs processing and mixing on audio information transmitted by the mobile terminal and audio



information of navigation, alarms, and the like transmitted by the two-wheeled vehicle, and sends mixed audio information to the helmet, such that a user is capable of acquiring audio information sent by a user terminal and information of navigation and the like sent by an electric vehicle without switching between audio information transmitted by the mobile terminal and the electric vehicle, thereby improving riding safety for users, and improving user experience.




图 7

[21] BN/N/2022/0088

[22] 19/07/2022

[54] Double Independent Control Unit-Based Intelligent Vehicle Control System And Vehicle

[71] SHARKGULF TECHNOLOGY (QINGDAO) CO., LTD. of Room 8206-1-4 (A), 2f Qiantongyuan Office Building, No. 44 Moscow Road, Qianyuan Bonded Port Area, Qingdao Area, China (Shandong) Pilot Free Trade Zone, Qingdao, Shandong 266000, China

[72] 1. LIU, KE
2. HU, HUI

[74] Messrs. HENRY GOH & CO. SDN. BHD. of AIP Law of Unit Nos. 405A-410A 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam

[31][32][33]

No. 202010057099.4 Date: 19 January 2020 Country: China

[86] PCT/CN2021/071001

[87] WO/2021/143630

[51] G05B 9/03, G05B 19/418

[57] A double independent control unit-based intelligent vehicle control system and a



corresponding vehicle (10). The intelligent vehicle control system comprises a locomotive end and a cloud server (80). The locomotive end comprises a first control unit (11) and a second control unit (12), and the first control unit (11) and the second control unit (12) can operate independently and perform data exchange in real time; the first control unit (11) monitors an operating state of the vehicle (10) in real time and transmits at least a part of operating state data to the second control unit (12) in real time, and the first control unit (11) controls operation of the vehicle (10) according to an internal predetermined instruction and a control instruction received from the second control unit (12); the second control unit (12) receives the data transmitted by the first control unit (11) and sends at least a part of the received data to the cloud server (80), and moreover, the second control unit (12) receives a control instruction from the cloud server (80) and forwards the control instruction for controlling the operation of the vehicle (10) to the first control unit (11).




图 2

[21] BN/N/2022/0089

[22] 26/07/2022

[54] Coronavirus Rna Vaccines

[71] MODERNATX, INC. of 200 Technology Square, Cambridge, Massachusetts 02139
United States of America

[72] 1. STEWART-JONES, GUILLAUME
2. NARAYANAN, ELISABETH
3. BENNETT, HAMILTON
4. CARFI, ANDREA
5. METKAR, MIHIR
6. PRESNYAK, VLADIMIR

[74] Messrs. AIP LAW of Unit Nos. 405A-410A 4th Floor, Wisma Jaya Jalan Pemancha,
Bandar Seri Begawan BS8811, Brunei Darussalam

[31][32][33]

No. 62/967,006 Date: 28 January 2020 Country: United States of America

No. 62/971,825 Date: 07 February 2020 Country: United States of America

No. 62/002,094 Date: 30 March 2020 Country: United States of America



No. 62/009,005 Date: 13 April 2020 Country: United States of America
No. 62/016,175 Date: 27 April 2020 Country: United States of America

[86] PCT/US2021/015145

[87] WO/2021/154763

[51] A61K 39/12, A61K 39/215, A61P 11/00, A61P 31/14

[57] The disclosure relates to coronavirus ribonucleic acid (RNA) vaccines as well as methods of using the vaccines and compositions comprising the vaccines.




FIG. 1

[21] BN/N/2022/0090

[22] 02/08/2022

[54] Threaded Joint For Steel Pipe

[71] NIPPON STEEL CORPORATION of 6-1, Marunouchi 2-chome, Chiyoda-ku, Tokyo 1008071 Japan

VALLOUREC OIL AND GAS FRANCE of 54 Rue Anatole France, Aulnoye-Aymeries, 59620 France

[72] 1. WADA, AKIRA
2. OKU, YOUSUKE
3. ANDO, YOSHINORI

[74] Messrs. CCW PARTNERSHIP of 1st & 2nd Floors, Units 9 & 10 Block C, Kiarong Complex Lebuhraya Sultan Hassanal Bolkiah BE1318 P.O Box 2216 Bandar Seri Begawan, Brunei Darussalam


[31][32][33]
No. 2020-110341 Date: 26 June 2020 Country: Japan

[86] PCT/JP2021/015974

[87] WO/2021/261063

[51] F16L 15/04, F16L 15/06

[57] According to the present invention, the shear resistance of a first thread ridge 111 at the tip of a male thread 11 is improved by setting the curvature radius r_1 of a load-surface bottom portion of the first thread ridge 111 so as to be, when Th represents a thread ridge height, not less than $Th \times 0.14$, more preferably, not less than $Th \times 0.16$. Further, the high torque resistance is maintained by: increasing the number of thread ridges and increasing a contact area of the load surface by setting a thread pitch to be small; increasing the contact area of the load surface by setting only the curvature radius of the load-surface bottom portion of the first thread ridge at the tip of the male thread to be large, but setting the curvature radius of other portions to be small; and the like.



AA: Engagement range of female thread and male thread
BB: Female thread complete thread section
CC: Female thread incomplete thread section
DD: Male thread incomplete thread section
EE: Male thread complete thread section

[21] BN/N/2022/0091

[22] 08/08/2022

[54] Formulations Of Human Anti-Tsfp Antibodies And Methods Of Treating Inflammatory Disease



[71] AMGEN INC. of One Amgen Center Drive Thousand Oaks, California 91320-1799
United States of America

[72] 1. LUERAS, ALEXIS
2. SLOEY, CHRISTOPHER
3. TALLEY, CLEA

[74] Messrs. SPRUSON & FERGUSON PTE LTD c/o AIP Law of Unit Nos. 405A-410A
4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei
Darussalam

[31][32][33]

No. 62/976,007 Date: 13 February 2020 Country: United States of America
No. 63/148,105 Date: 10 February 2021 Country: United States of America

[86] PCT/US2021/017880

[87] WO/2021/163504

[51] A61K 39/395, A61K 9/00, A61K 9/08, A61K 47/18, A61K 47/26

[57] Provided herein are aqueous compositions comprising (a) an anti-TSLP antibody at a concentration greater than about 140 mg/mL, (b) a surfactant, and (c) at least one basic amino acid or a salt thereof. Also provided are aqueous compositions comprising aqueous compositions comprising (a) an anti-TSLP antibody at a concentration greater than about 140 mg/mL, (b) a surfactant, and (c) at least one calcium salt or magnesium salt. Related articles of manufacture, pre-filled syringes, and vials comprising the compositions of the present disclosure are also provided. Uses of the compositions for treating an inflammatory disease, e.g., atopic dermatitis, are provided herein. Also, methods of making a stable, liquid antibody comprising having a viscosity of less than about 100 cP is provided herein.

[21]	BN/N/2022/0092	[22]	09/08/2022
[54]	HPV Vaccine		
[71]	MERCK SHARP & DOHME LLC of 126 East Lincoln Avenue, Rahway, New Jersey 07065-0907, United States of America		
[72]	1. GINDY, MARIAN, E. 2. BILELLO, JOHN, P. 3. ESPESETH, AMY, S. 4. BETT, ANDREW, J. 5. FU, TONG-MING		



[74] Messrs. SPRUSON & FERGUSON PTE LTD of AIP Law, Unit Nos. 405A-410A 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam

[31][32][33]

No. 62/976,673 Date: 14 February 2020 Country: United States of America

[86] PCT/US2021/017157

[87] WO/2021/16300

[51] A61K 39/12, A61P 31/20

[57] The present disclosure provides, among other things, a pharmaceutical composition that includes a lipid nanoparticle adjuvant and an anti-human papillomavirus (HPV) comprising HPV virus-like particles (VLPs) of at least one type of human papillomavirus (HPV) selected from the group consisting of HPV types: 6, 11, 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 55, 56, 58, 59, 66, 68, 73, and 82.




FIG.1A

[21] BN/N/2022/0093

[22] 15/08/2022

[54] Early-Warning System, Method, And Apparatus For Steering Of Two-Wheeled Vehicle, And Corresponding Two-Wheeled Vehicle

[71] SHARKGULF TECHNOLOGY (QINGDAO) CO., LTD. of Room 8206-1-4 (A), 2f, Qiantongyuan Office Building, No. 44 Moscow Road, Qianwan Bonded Port Area, Qingdao Area, China (Shandong) Pilot Free Trade Zone, Qingdao, Shandong 266000, China

[72] 1. CHEN, LIJING
2. BILLEDEAU, ROLAND, JOSEPH
3. LI, JIM

[74] Messrs. HENRY GOH & CO. SDN. BHD. c/o AIP Law of Unit Nos. 405A-410A 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam

[31][32][33]
No. 202010127193.2 Date: 28 February 2020 Country: China

[86] PCT/CN2021/071002

[87] WO/2021/169629

[51] B62J 50/22, B62J 45/00, G08B 21/02, A42B 3/30, H04L 29/08

[57] An early-warning system, method and device (600) for steering of a two-wheeled vehicle, and a corresponding two-wheeled vehicle (10). The two-wheeled vehicle (10) comprises a display device (40). The early-warning system for steering of a two-wheeled vehicle comprises: a first control system (12) and a second control system (11); the first control system and the second control system can operate independently and can exchange data in real time; the first control system (12) monitors the steering state of the two-wheeled vehicle (10) in real time, generates steering state data, generates early-warning state data according to the steering state data, and transmits, to the second control system (11), at least a part of the steering state data and the early-warning state data in real time; the first control system is also used for controlling the operation of the two-wheeled vehicle (10) according to a received instruction; and the second control system (11) receives the steering state data and the early-warning state data transmitted by the first control system (12), generates early-warning information according to the early-warning state data, and controls the display of the display device (40) according to the steering state data and/or the early-warning information.




图 3

[21] BN/N/2022/0094 [22] 15/08/2022

[54] Formulations Of Human Anti-Tsfp Antibodies And Methods Of Using The Same

[71] AMGEN INC. of One Amgen Center Drive Thousand Oaks,, California 91320-1799
United States of America

[72] 1. ROSCIEN, LAUREN



2. LITOWSKI, JENNIFER

[74] **Messrs. SPRUSON & FERGUSON PTE LTD c/o AIP Law of Unit Nos. 405A-410A 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam**

[31][32][33]

No. 62/978,201 Date: 18 February 2020 Country: United States of America

[86] **PCT/US2021/018561**

[87] **WO/2021/168100**

[51] **A61K 39/395, C07K 16/24**

[57] **Provided herein are compositions comprising greater than about 100 mg/mL of an anti-TSLP antibody, a surfactant, proline, and a buffer comprising greater than about 100 mg/mL of an anti-TSLP antibody, a surfactant, proline, and a buffer. Methods for treating an inflammatory disease in a subject are further provided.**

[21] **BN/N/2022/0095** [22] **18/08/2022**

[54] **A Fluid Diverter Tool, System And Method Of Diverting A Fluid Flow In A Well**

[71] **HYDRA SYSTEMS AS of Postboks 182, 4098 Tananger, Norway**

[72] **1. IUELL, MARKUS
2. JENSEN, ROY INGE
3. ØSTVOLD, ARNOLD**

[74] **Messrs. HENRY GOH & CO. SDN. BHD. c/o AIP Law of Unit Nos. 405A-410A 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam**

[31][32][33]

No. 20200284 Date: 09 March 2020 Country: Norway

[86] **PCT/NO2021/050059**


[87] **WO/2021/182968**

[51] **E21B 37/00, E21B 37/08**

[57] **A fluid diverter tool (16), system and method of diverting a fluid flow in a well (2), comprising: - a tubular mandrel (48) and a packer element (30) affixed onto an**



exterior thereof and operable to sealingly engage an inside of a pipe body (4) to divert a flow of a treatment fluid (26, 46) outwards through holes (10) formed in the pipe body (4); and - a pressure relief device (40) operable to open and relieve pressure from one side (38) to another side (34) of the packer element (30) when exposed to a given pressure differential acting across the pressure relief device (40) from said one side (38) of the packer element (30), the pressure relief device (40) also adapted to close when exposed to a lower than said given pressure differential acting thereacross from said one side (38) of the packer element (30).





[86] PCT/KR2018/009998

[87] WO/2019/045452

[51] C07K 16/24, A61K 9/00, A61K 47/14, A61K 47/26, A61K 47/18, A61K 39/00

[57] The present invention relates to a method for treating a TNF α -related disease by subcutaneously administering an antibody (anti-TNF α antibody) or an antigen-binding fragment thereof that binds to TNF α . The treatment method, composition, kit or use thereof according to the present invention provides an advantage of increased patient satisfaction, through the improvement of convenience and enhancement of the quality of life, by reducing the time taken for administration compared to intravenous injections and decreasing the time that patients stay in a hospital.

[21] BN/N/2022/0097 [22] 27/08/2022

[54] Anti-Human CD19 Antibodies

[71] ELI LILLY AND COMPANY of Lilly Corporate Center, Indianapolis, Indiana 46285, United States of America

[72] 1. ALLAN, BARRETT
2. BOYLES, JEFFREY STREETMAN
3. BUDELSKY, ALISON LEE SIM
4. NA, SONGQING
5. RUBTSOVA, KIRA VLADIMIROVNA
6. ZHANG, GUIFENG

[74] Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD c/o AIP Law of Unit Nos. 405A-410A 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam

[31][32][33]
No. 62/983,093 Date: 28 March 2020 Country: United States of America

[86] PCT/US2021/018989

[87] WO/2021/173471

[51] C07D 16/28, A61K 39/395, A61K 37/00, A61P 37/06

[57] The present disclosure relates to antibodies that bind human CD19 (anti-human CD19 antibodies or anti-human CD19 antibodies), compositions comprising such anti-human CD19 antibodies, and methods of using such anti-human CD19 antibodies.



[21] BN/N/2022/0098 [22] 29/08/2022

[54] **Anti- Muc1-Sea Antibodies**

[71] **BIOMODIFYING, LLC** of 601 Rockford Road, Silver Spring, Maryland 20902, United States of America
RAMOT AT TEL-AVIV UNIVERSITY LTD. OF P.O. BOX 39296, 6139201 Tel-Aviv, Israel

[72] 1. RUBINSTEIN, DANIEL
2. WRESCHNER, DANIEL

[74] **Messrs. MARKS & CLERK SINGAPORE LLP** c/o AIP Law of Unit Nos. 405A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam

[31][32][33]
No. 62/991,077 Date: 18 March 2020 Country: United States of America

[86] PCT/IL2021/050269

[87] WO/2021/186427

[51] C07K 16/30, A61K 47/68

[57] The present invention provides isolated monoclonal antibodies which bind to the MUC1 SEA domain. The invention also concerns the use of these antibodies in therapeutic and diagnostic methods.

[21] BN/N/2022/0099 [22] 06/09/2022

[54] **Compositions And Methods For Inducing An Immune Response**

[71] **OXFORD UNIVERSITY INNOVATION LIMITED** of Buxton Court, 3 West Way, Oxford, Oxfordshire OX2 0JB

[72] 1. GILBERT, SARAH C.
2. LAMBE, TERESA
3. SEBASTIAN, SARAH

[74] **Messrs. AIP LAW** of Unit Nos. 405A-410A 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam

[31][32][33]

No. 2003670.3 Date: 13 March 2020 Country: United Kingdom
No. 2006608.0 Date: 05 May 2020 Country: United Kingdom
No. 2007062.9 Date: 13 May 2020 Country: United Kingdom
No. 2009239.1 Date: 17 June 2020 Country: United Kingdom
No. 2010569.8 Date: 09 July 2020 Country: United Kingdom
No. 2016922.3 Date: 26 October 2020 Country: United Kingdom
No. 2017284.7 Date: 30 October 2020 Country: United Kingdom
No. 2017677.2 Date: 09 November 2020 Country: United Kingdom
No. 2018410.7 Date: 23 November 2020 Country: United Kingdom
No. 2018718.3 Date: 27 November 2020 Country: United Kingdom
No. 2100034.4 Date: 04 January 2021 Country: United Kingdom

[86] PCT/GB2021/050602

[87] WO/2021/181100

[51] A61K 39/12, A61P 31/14, A61K 39/00

[57] The invention relates to a composition comprising a viral vector, the viral vector comprising nucleic acid having a polynucleotide sequence encoding the spike protein from the coronavirus SARS-C0V2, characterised in that said viral vector is an adenovirus based vector. The invention also relates to uses of such a composition and methods of treatment.




FIG. 1

[21] BN/N/2022/0100

[22] 12/09/2021

[54] Method For Treatment Of Covid-19-Associated Conditions

[71] RIGEL PHARMACEUTICALS, INC. of 1180 Veterans Boulevard, South San Francisco, California 94080, United States of America

[72] 1. MASUDA, ESTEBAN
2. MARKOVTSOV, VADIM

[74] Messrs. AIP LAW of Unit Nos. 405A-410A 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam

[31][32][33]

No. 62/988,876 Date: 12 March 2020 Country: United States of America

No. 63/038,570 Date: 12 June 2020 Country: United States of America

[86] PCT/US2021/021951

[87] WO/2021/183790

[51] A61K 39/395

[57] Provided herein are a variety of methods that involve administering fostamatinib, an active component thereof or a pharmaceutically acceptable salt thereof to a patient. In some embodiments, the method may comprise administering fostamatinib, an active component thereof or a pharmaceutically acceptable salt thereof to a patient having or suspected of having a COVID-19 infection. In some embodiments, the method may comprise administering fostamatinib, an active component thereof or a pharmaceutically acceptable salt thereof to a patient having, suspected of having or expected to develop acute respiratory distress syndrome, acute kidney injury, and/or thrombosis. In some embodiments, the method may comprise administering fostamatinib, an active component thereof or a pharmaceutically acceptable salt thereof to a patient having, suspected of having or expected to develop symptoms associated with a cytokine response. Aspects of the methods may further include identifying a patient with kidney malfunction, e.g., acute kidney injury, and/or thrombosis.




FIG. 3

[21] BN/N/2022/0101

[22] 14/09/2022

[54] Pyrrolopyrimidine Amines As Complement Inhibitors



[71] **BIOCRYST PHARMACEUTICALS, INC.** of 4505 Emperor Blvd. Suite 200 Durham, NC 27703 United States of America

[72] 1. KOTIAN, PRAVIN, L.
2. BABU, YARLAGADDA, S.
3. WU, MINWAN
4. DANG, ZHAO
5. NGUYEN, TRUNG XUAN
6. RAMAN, KRISHNAN

[74] **Messrs. MIRANDAH ASIA (SINGAPORE) PTE LTD** c/o AIP Law of Unit Nos. 405A-410A 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam


[31][32][33]
No. 63/004,799 Date: 03 April 2020 Country: United States of America

[86] PCT/US2021/025547

[87] WO/2021/202977

[51] A61K 31/519, C07D 207/02, C07D 265/28

[57] Disclosed are compounds of formula (I), and pharmaceutically acceptable salts thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.



[21] BN/N/2022/0102 [22] 15/09/2022

[54] Crystal

[71] **NIPPON SHINYAKU CO., LTD.** of 14, Kisshoin Nishinoshio Monguchicho, Minami-Ku, Kyotoshi, Kyoto 601-8550, Japan

[72] 1. TOSHIO FUJIWARA



[74] **Messrs. MARKS & CLERK SINGAPORE LLP c/o AIP Law of Unit Nos. 405A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam**

[31][32][33]
No. 2017-187296 Date: 28 September 2017 Country: Japan

[86] **PCT/JP2018/035828**

[87] **WO/2019/065792**

[51] **C07D 241/20, A61K 31/4965, A61P 1/04, A61P 7/02, A61P 9/00, A61P 9/08, A61P 9/10, A61P 9/12, A61P 11/00, A61P 11/06, A61P 11/14, A61P 13/12, A61P 17/02, A61P 25/00, A61P 43/00**

[57] **The main purpose of the present invention is to provide a novel crystal of 2-[4-[N-(5,6-diphenylpyrazine-2-yl)-N-isopropylamino]butyloxy} acetic acid (hereinafter "compound B"). A type I crystal of compound B with which, in a powder X-ray diffraction spectrum obtained by using CuK α radiation ($\lambda=1.54$ Å), the diffraction angle (2θ) shows peaks at the diffraction angles 6.4°, 8.1°, 9.5°, 10.9°, 13.2°, 15.7°, 17.0°, 19.5°, 20.3°, 21.0°, and 22.8°. A type II crystal of compound B with which, in a powder X-ray diffraction spectrum obtained by using CuK α radiation ($\lambda=1.54$ Å), the diffraction angle (2θ) shows peaks at the diffraction angles 9.6°, 11.4°, 11.7°, 16.3°, 17.5°, 18.5°, 18.7°, 19.9°, 20.1°, 21.0°, and 24.6°.**

[21] **BN/N/2022/0103** [22] **19/09/2022**

[54] **Oxazolidinone Compound And Methods Of Use Thereof As An Antibacterial Agent**

[71] **MERCK SHARP & DOHME LLC of 126 East Lincoln Avenue Rahway, NJ 07065 United States of America**

[72] **1. CROWLEY, BRENDAN, M.
2. NANTERMET, PHILIPPE
3. OLSEN, DAVID, B.
4. SUZUKI, TAKAO
5. YANG, LIHU
6. YOU, LANYING**

[74] **Messrs. AIP LAW of Unit Nos. 405A-410A 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam**

[31][32][33]
No. PCT/CN2020/080359 Date: 20 March 2020 Country: China




[86] PCT/US2021/022652

[87] WO/2021/188606

[51] A61K 31/541, A61P 31/04, A61P 31/06, C07D 279/00

[57] The present invention relates to the oxazolidinone compound of Formula (I): and pharmaceutically acceptable salts thereof. The present invention also relates to compositions containing the compound of Formula (I). The invention also provides methods for inhibiting growth of mycobacterial cells as well as a method of treating mycobacterial infections by *Mycobacterium tuberculosis* by administering a therapeutically effective amount of Formula (I) and/or a pharmaceutically acceptable salt thereof, or a composition comprising such compound and/or salt.



[21] BN/N/2022/0104

[22] 20/09/2022

[54] Human Monoclonal Antibodies To Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2)

[71] VANDERBILT UNIVERSITY INC. of 305 Kirkland Hall, 2201 West End Avenue, Nashville Tennessee 37240, United States of America

[72] 1. CROWE, JR., JAMES E.
2. ZOST, SETH
3. CARNAHAN, ROBERT
4. GILCHUK, PAVLO

[74] Messrs. AIP Law of Unit Nos. 404A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam

[31][32][33]

No. 63/000,299 Date: 26 March 2020 Country: United States of America

No. 63/002,896 Date: 31 March 2020 Country: United States of America

No. 63/003,716 Date: 04 April 2020 Country: United States of America

No. 63/023,545 Date: 12 May 2020 Country: United States of America

No. 63/024,204 Date: 13 May 2020 Country: United States of America

No. 63/024,248 Date: 13 May 2020 Country: United States of America

No. 63/027,173 Date: 19 May 2020 Country: United States of America

No. 63/037,984 Date: 11 June 2020 Country: United States of America



No. 63/040,224 Date: 17 June 2020 Country: United States of America
No. 63/040,246 Date: 17 June 2020 Country: United States of America
No. 63/142,196 Date: 27 January 2021 Country: United States of America
No. 63/161,890 Date: 16 March 2021 Country: United States of America

[86] PCT/US2021/024215

[87] WO/2021/195418

[51] C07K 16/10, G01N 33/569, G01N 33/577, A61K 39/00

[57] The present disclosure is directed to antibodies binding to and neutralizing the coronavirus designated SARS-CoV-2 and methods for use thereof.

[21] BN/N/2022/0105 [22] 20/09/2022

[54] Modified Alkylsulfonic Acid And Uses Thereof

[71] SIXRING INC. of 1500, 140-10 Avenue SE Calgary, AB T2G OR1, Canada

[72] 1. PURDY, CLAY
2. WEISSENBERGER, MARKUS
3. WYNNYK, KYLE G.
4. DAWSON, KARL W.

[74] Messrs. GATEWAY LAW CORPORATION c/o AIP Law of Unit Nos. 405A-410A 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam

[31][32][33]

No. 3,074,198 Date: 28 February 2020 Country: Canada

[86] PCT/CA2021/000018

[87] WO/2021/168538

[51] D21C 3/06

[57] Method of delignification of plant material, said method comprising: providing said plant material comprising cellulose fibers and lignin; exposing said plant material requiring to a composition comprising: alkane sulfonic acid; and a peroxide, wherein said alkylsulfonic acid and peroxide are present in a molar ratio ranging from 1:1 to 15:1 and the time of exposure is sufficient to remove substantially all of the lignin present on said plant material. Compositions capable of achieving delignification are also disclosed.



[21] BN/N/2022/0106 [22] 20/09/2022

[54] Modified Sulfuric Acid And Uses Thereof

[71] SIXRING INC. of 1500, 140-10 Avenue SE Calgary, AB T2G OR1, Canada

[72] 1. PURDY, CLAY
2. WEISSENBERGER, MARKUS
3. WYNNYK, KYLE G.
4. DAWSON, KARL W.

[74] Messrs. GATEWAY LAW CORPORATION c/o AIP Law of Unit Nos. 405A-410A 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam

[31][32][33]
No. 3,074,194 Date: 28 February 2020 Country: Canada

[86] PCT/CA2021/000017

[87] WO/2021/168537

[51] D21C 3/06

[57] An aqueous composition comprising: sulfuric acid; a compound comprising an amine moiety; a compound comprising a sulfonic acid moiety; and a peroxide. Said composition being capable of delignifying biomass.




Figure 1

[21] BN/N/2022/0107 [22] 20/09/2022

[54] Sulfuric Acid Composition And Uses Thereof

[71] SIXRING INC. of 1500, 140-10 Avenue SE Calgary, AB T2G OR1, Canada



[72] 1. PURDY, CLAY
2. WEISSENBERGER, MARKUS
3. WYNNYK, KYLE G.
4. DAWSON, KARL W.

[74] Messrs. GATEWAY LAW CORPORATION c/o AIP Law of Unit Nos. 405A-410A 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam

[31][32][33]
No. 3,074,199 Date: 28 February 2020 Country: Canada

[86] PCT/CA2021/000016

[87] WO/2021/168536

[51] D21C 3/06, C01B 17/69. C09K 3/00

[57] An aqueous acid composition comprising sulfuric acid, a compound comprising an amine moiety and a sulfonic acid moiety and optionally a peroxide. The use of the composition in treating biomass is also disclosed.




Figure 1

[21] BN/N/2022/0108 [22] 21/09/2022

[54] Method For Treating IDH1 Inhibitor-Resistant Subjects

[71] ELI LILLY AND COMPANY of Lilly Corporate Center Indianapolis, Indiana 46285 United States of America

[72] 1. BROOKS, NATHAN, ARTHUR
2. GILMOUR, RAYMOND

[74] Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD c/o AIP Law of Unit Nos. 404A-410A 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam



[31][32][33]

No. 62/993,135 Date: 23 March 2020 Country: United States of America

No. 63/024,761 Date: 14 May 2020 Country: United States of America


No. 63/151,905 Date: 22 February 2021 Country: United States of America

[86] PCT/US2021/023452

[87] WO/2021/194953

[51] A61K 31/5395, A61P 35/00

[57] The present invention relates to the treatment of human cancer subjects with a mutant isocitrate dehydrogenase 1 inhibitor of formula I.



[21] BN/N/2022/0109

[22] 21/09/2022

[54] Combination Therapy With A Mutant Idh Inhibitor And A Bcl-2 Inhibitor

[71] **BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM** of 210 West 7th Street Austin, Texas 78701, United States Of America

**ELI LILLY AND COMPANY of Lilly Corporate Center Indianapolis,
Indiana 46285 United States of America**

[72] 1. BROOKS, NATHAN, ARTHUR
2. DINARDO, COURTNEY
3. GILMOUR, RAYMOND
4. KONOPLEVA, MARINA
5. SALAMA, VIVIAN

[74] Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD c/o AIP Law of Unit Nos. 404A-410A 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam

[31][32][33]

No. 62/993.166 Date: 23 March 2020 Country: United States of America

No. 63/024.743 Date: 14 May 2020 Country: United States of America


[86] PCT/US2021/023442



[87] WO/2021/194950

[51] A61K 31/5395, A61K 31/635, A61K 31/404, A61P 35/00

[57] The present invention relates to combination therapy with a mutant IDH inhibitor of Formula (I) and a Bcl-2 inhibitor, for the treatment of cancer.



[21] BN/N/2022/0110

[22] 21/09/2022

[54] Combination Therapy With A Mutant Idh Inhibitor

[71] ELI LILLY AND COMPANY of Lilly Corporate Center Indianapolis, Indiana 46285
United States of America

[72] 1. BROOKS, NATHAN, ARTHUR
2. GILMOUR, RAYMOND

[74] Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD c/o AIP Law of Unit Nos. 404A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam

[31][32][33]

No. 62/993,254 Date: 23 March 2020 Country: United States of America

No. 63/024,713 Date: 14 May 2020 Country: United States of America


No. 63/053,875 Date: 20 July 2020 Country: United States of America

[86] PCT/US2021/023436

[87] WO/2021/194946

[51] A61K 31/5395, A61K 31/553, A61K 31/706, A61K 31/7069, A61P 35/00

[57] The present invention relates to combination therapy with (a) a mutant IDH inhibitor having the Formula I and (b) one or more of an antimetabolite agent, a hypomethylating agent, and a mutant Flt3 (Flt3) inhibitor, for the treatment of cancer.




[21]	BN/N/2022/0111	[22]	28/09/2022
[54]	Preparation Of MCL-1 Inhibiting Compound By Methylation In The Presence Of Water		
[71]	AMGEN INC. of One Amgen Center Drive Thousand Oaks, California 91320-1799, United States of America		
[72]	1. ACHMATOWICZ, MICHAEL 2. CUI, SHENG 3. HWANG, TSANG-LIN 4. LANGILLE, NEIL FRED 5. TOM, JANINE K. 6. HUCKLE, JAMES E. 7. STEC, MARKIAN 8. WU, TIAN 9. BROWN, SEAN P		
[74]	Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD c/o AIP Law of Unit Nos. 404A-410A 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam		
[31][32][33]	No. 63/002,629 Date: 31 March 2020 Country: United States of America No. 63/070,630 Date: 26 August 2020 Country: United States of America No. 63/084,367 Date: 28 September 2020 Country: United States of America		
[86]	PCT/US2021/024779		
[87]	WO/2021/202452		
[51]	C07D 519/00, A61P 35/00, A61K 31/553		
[57]	Disclosed herein is an improved process for the synthesis of compound (A): (A), or a salt or solvate thereof via methylation of compound (B): (B), or a salt or solvate		



thereof, a crystalline hydrate of compound A, and pharmaceutical formulations comprising a crystalline hydrate of compound (A).

FIG. 1



[21] BN/N/2022/0112

[22] 29/09/2022

[54] Conjugates For Selective Responsiveness To Vicinal Diols

[71] PROTOMER TECHNOLOGIES INC. of c/o Eli Lilly And Company, Lilly Corporate Center P.O. Box 6288, Indianapolis, Indiana 46206-6288, United States of America

[72]

1. MAHDAVI, ALBORZ
2. SPENCER, RYAN KELLY
3. HALE, JACK JOSEPH
4. LIANG, JINGXIN
5. SHAKER, MIRNA EKRAM ANWAR
6. CHEN, DIAO
7. MALI, SACHITANAND

[74] Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD c/o AIP Law of Unit Nos. 404A-410A 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam

[31][32][33]

No. 63/002,662 Date: 31 March 2020 Country: United States of America

[86] PCT/US2021/025261

[87] WO/2021/202802

[51] A61K 47/54, C07F 5/02, C07K 14/62 A61K 38/28, A61P 3/10

[57] Embodiments of the present disclosure relate to sensors that can selectively bind to specific vicinal diols in the presence of other diols. These boronated vicinal diol-



responsive sensor compounds can sense levels of specific vicinal diols and respond to these molecules in the body. In certain embodiments, the vicinal diol is a cis diol, for example, a hexose such as glucose. In certain embodiments the sensors are conjugated to a drug substance, and the sensors may change the biophysical characteristics, pharmacokinetics, and/or activity of the drug substance in response to the vicinal diol. The drug substance may be or include a polypeptide, such as an insulin, a human endocrine or incretin peptide, or an analogue thereof, and may contain one or more modified amino acids containing a vicinal diol-responsive sensor.

[21]	BN/N/2022/0113	[22]	29/09/2022
[54]	Allosteric Chromenone Inhibitors Of Phosphoinositide 3-Kinase (Pi3k) For The Treatment Of Diseases Associated With PI3k Modulation		
[71]	PETRA PHARMA CORPORATION of 450 E 29th ST, SUITE 506, New York, New York 10016, United States of America		
[72]	<ol style="list-style-type: none">1. ANDERSON, ERIN DANIELLE2. ARONOW, SEAN DOUGLAS3. BOYLES, NICHOLAS A.4. DAHLGREN, MARKUS K.5. FENG, SHULU6. GERASYUTO, ALEKSEY I.7. HICKEY, EUGENE R.8. IRVIN, THOMAS COMBS9. KESICKI, EDWARD A.10. KLIPPEL-GIESE, ANKE11. KNIGHT, JENNIFER LYNN12. KOLAKOWSKI, GABRIELLE R.13. KUMAR, MANOJ14. LONG, KATELYN FRANCES15. MAYNE, CHRISTOPHER GLENN16. MCELLIGOTT, DAVID L.17. MCLEAN, JOHNATHAN ALEXANDER18. PUCA, LOREDANA19. RAVI, KANNAN KARUKURICHI20. SEVERANCE, DANIEL LEE21. WELCH, MICHAEL BRIAN22. WIDJAJA, TIEN		
[74]	Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD c/o AIP Law of Unit Nos. 404A-410A 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam		
[31][32][33]			




No. 63/005,096 Date: 03 April 2020 Country: United States of America

[86] PCT/US2021/025521

[87] WO/2021/202964

[51] C07D 405/04, A61P 3/00, A61K 31/403, A61P 19/00, C07D 405/14, A61P 35/00, C07D 471/04

[57] The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I), or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein R₁, R₂, R₃, R₄, R₅, R₆, R₇, R₈, R₉, W, X, Y, s, and Ring A are as described herein.



[21] BN/N/2022/0114 [22] 29/09/2022

[54] Ripik Inhibitors

[71] RIGEL PHARMACEUTICALS, INC. of 1180 Veterans Boulevard, South San Francisco, California 94080, United States of America

[72] 1. DARWISH, lhab
2. LUO, Zhushou
3. TAYLOR, Vanessa

[74] Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD c/o AIP Law of Unit Nos. 404A-410A 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam

[31][32][33]

No. 63/004,404 Date: 02 April 2020 Country: United States of America

[86] PCT/US2021/025598

[87] WO/2021/203011

[51] C07D 471/04, C07D 498/04, C07D 498/10, A61P 17/00, A61K 31/553, A61P 25/00, A61P 31/00, A61P 35/00



[57] Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.



**REGISTRAR OF PATENT
BRUNEI DARUSSALAM**

PATENTS RULES [S 11/2013]

PATENT RENEWAL APPLICATION

Patent No.: BN/N/2018/0064
Date of Grant: 03 January, 2017
Annuity: 6th Year
Applicant(s) / Proprietor(s): GRABTAXI HOLDINGS PTE LTD
Title of Invention: System And Method For Driver Selection

Patent No.: BN/N/2016/0082
Date of Grant: 24 April, 2015
Annuity: 8th Year
Applicant(s) / Proprietor(s): MEIER SANITECH PTE LTD
Title of Invention: A Sanitary Valve Device And Assembly

Patent No.: BN/N/2017/0096
Date of Grant: 16 May, 2016
Annuity: 5th Year
Applicant(s) / Proprietor(s): AHO, RICHARD, E.
Title of Invention: Cavitation Engine

Patent No.: RE/R/2016/0032
Date of Grant: 23 March, 2016
Annuity: 7th Year
Applicant(s) / Proprietor(s): MERCK SHARP & DOHME CORP.



Title of Invention: Inhibitors Of Hepatitis C Virus Replication

Patent No.: RE/R/2013/0045

Date of Grant: 31 May, 2012

Annuity: 11th Year

Applicant(s) / Proprietor(s): PTC THERAPEUTICS, INC.

Title of Invention: Compositions Of An Orally Active 1,2,4-Oxadiazole For Nonsense Mutation Suppression Therapy

Patent No.: RE/R/2013/0061

Date of Grant: 20 July, 2011

Annuity: 12th Year

Applicant(s) / Proprietor(s): SHOWCASE INC.

Title of Invention: Web Display Program Conversion System, Web Display Program Conversion Method And Program For Converting Web Display Program

Patent No.: RE/R/2014/0001

Date of Grant: 24 May, 2012

Annuity: 11th Year

Applicant(s) / Proprietor(s): UNITED PIPELINES ASIA PACIFIC PTE LIMITED

Title of Invention: Austenitic Stainless Steel

Patent No.: RE/R/2014/0028

Date of Grant: 22 April, 2010

Annuity: 13th Year

Applicant(s) / Proprietor(s): F.HOFFMAN-LA ROCHE AG

Title of Invention: Methods For Improving Pharmacokinetics



Patent No.:	RE/R/2014/0043
Date of Grant:	02 June, 2014
Annuity:	9th Year
Applicant(s) / Proprietor(s):	INDUSTRIAL GALVANIZERS CORPORATION PTY LTD
Title of Invention:	Improved Road Barrier

Patent No.:	RE/R/2015/0031
Date of Grant:	30 April, 2014
Annuity:	9th Year
Applicant(s) / Proprietor(s):	ACCELERON PHARMA INC.
Title of Invention:	Anti-Activin A Or B Antibodies And Use Thereof For Promoting Bone Growth

Patent No.:	RE/R/2016/0015
Date of Grant:	26 May, 2015
Annuity:	8th Year
Applicant(s) / Proprietor(s):	BAVARIAN NORDIC A/S
Title of Invention:	Use Of A Modified Poxvirus For The Rapid Induction Of Immunity Against A Poxvirus Or Other Infectious Agents

Patent No.:	RE/R/2017/0024
Date of Grant:	16 May, 2016
Annuity:	7th Year
Applicant(s) / Proprietor(s):	ONO PHARMACEUTICAL CO., LTD.
Title of Invention:	Purinone Derivative



Patent No.: RE/R/2018/0004
Date of Grant: 31 May, 2017
Annuity: 6th Year
Applicant(s) / Proprietor(s): NIPPON STEEL & SUMITOMO METAL CORPORATION VALLOUREC MANNESMANN OIL & GAS FRANCE
Title of Invention: Threaded Joint For Pipes

Patent No.: RE/R/2018/0017
Date of Grant: 20 April, 2017
Annuity: 6th Year
Applicant(s) / Proprietor(s): ABBVIE BAHAMAS LTD.
Title of Invention: Anti-Viral Compounds To Treat Hcv Infection

Patent No.: RE/R/2018/0019
Date of Grant: 31 May, 2017
Annuity: 6th Year
Applicant(s) / Proprietor(s): BAVARIAN NORDIC A/S
Title of Invention: Immediate Protection Against Pathogens Via Mva

Patent No.: RP/R/2010/0008
Date of Grant: 30 April, 2007
Annuity: 16th Year
Applicant(s) / Proprietor(s): ELI LILLY AND COMPANY
Title of Invention: Diaryl Ethers As Opioid Receptor Antagonist



Patent No.:	BN/N/2016/0085
Date of Grant:	16 June, 2015
Annuity:	8th Year
Applicant(s) / Proprietor(s):	NIPPON STEEL & SUMITOMO METAL CORPORATION VALLOUREC OIL AND GAS FRANCE
Title of Invention:	Threaded Joint For Steel Pipes

Patent No.:	BN/N/2016/0088
Date of Grant:	19 June, 2015
Annuity:	8th Year
Applicant(s) / Proprietor(s):	NIPPON STEEL & SUMITOMO METAL CORPORATION VALLOUREC OIL AND GAS FRANCE
Title of Invention:	Threaded Coupling For Steel Piping

Patent No.:	BN/N/2017/0082
Date of Grant:	5 August, 2016
Annuity:	7th Year
Applicant(s) / Proprietor(s):	CS CONSTRUCTION & GEOTECHNIC PTE LTD
Title of Invention:	System And Method For Securing, Moving And Placing A Pile Or Heavy Elongated Object

Patent No.:	BN/N/2018/0098
Date of Grant:	2 May, 2017
Annuity:	6th Year
Applicant(s) / Proprietor(s):	FOURTH MILITARY MEDICAL UNIVERSITY
Title of Invention:	Humanized Anti-Basigin Antibodies And The Use Thereof



Patent No.:	BN/N/2018/0105
Date of Grant:	24 May, 2017
Annuity:	6th Year
Applicant(s) / Proprietor(s):	BISN TEC LTD
Title of Invention:	Combined Well Plug/Chemical Heater Assemblies For Use In Down-Hole Operations And Associated Heater Cartridges

Patent No.:	BN/N/2018/0106
Date of Grant:	24 May, 2017
Annuity:	6th Year
Applicant(s) / Proprietor(s):	BISN TEC LTD
Title of Invention:	Down-Hole Chemical Heater And Methods Of Operating Such

Patent No.:	BN/R/2020/0006
Date of Grant:	24 November, 2010
Annuity:	12th Year
Applicant(s) / Proprietor(s):	MEDIMMUNE LIMITED
Title of Invention:	Targeted Binding Agents Against B7-H1

Patent No.:	RE/R/2012/0012
Date of Grant:	21 May, 2003
Annuity:	20th Year
Applicant(s) / Proprietor(s):	NOVARTIS AG
Title of Invention:	1 - (3, 4 - Dimethylphenyl) -1 , 5 - Dihydro - Methyl - 5 - Oxo - 4h - Pyrazol - 4 - Ylidene Hydrazine - 2' - Hydroxyl - 1, 1' - Biphenyl - 3 - Carboxylic Acid



Patent No.:	RE/R/2013/0025
Date of Grant:	31 May, 2012
Annuity:	11th Year
Applicant(s) / Proprietor(s):	DEBIOPHARM INTERNATIONAL SA
Title of Invention:	Slow Release Pharmaceutical Composition Made Of Microparticles

Patent No.:	RE/R/2014/0032
Date of Grant:	14 June, 2013
Annuity:	10th Year
Applicant(s) / Proprietor(s):	CURIS, INC.
Title of Invention:	Fused Amino Pyridine As HSP90 Inhibitors

Patent No.:	RE/R/2014/0069
Date of Grant:	14 June, 2013
Annuity:	10th Year
Applicant(s) / Proprietor(s):	JANSSEN PHARMACEUTICA N.V.
Title of Invention:	Fumarate Salt Of (Alpha S, Beta R)-6- Bro,O-Alpha-[2-(Dimethylamino)Ethyl]-2-Methoxy-Alpha-1-Naphthalenyl-Beta-Phenyl-3-Quinolineethanol

Patent No.:	RE/R/2015/0032
Date of Grant:	21 May, 2014
Annuity:	9th Year
Applicant(s) / Proprietor(s):	MERIDIAN MEDICAL TECHNOLOGIES
Title of Invention:	Automatic injector



Patent No.:	RE/R/2015/0033
Date of Grant:	25 June, 2014
Annuity:	9th Year
Applicant(s) / Proprietor(s):	ASTRAZENECA AB
Title of Invention:	Pyrrolo [2, 3 -D] Pyrimidin Derivatives As Protein Kinase B Inhibitors

Patent No.:	RE/R/2015/0040
Date of Grant:	28 May, 2014
Annuity:	9th Year
Applicant(s) / Proprietor(s):	ACCELERON PHARMA, INC.
Title of Invention:	Variants derived from ActRIIB and uses therefor

Patent No.:	RE/R/2016/0010
Date of Grant:	15 May, 2015
Annuity:	8th Year
Applicant(s) / Proprietor(s):	SUMITOMO METAL INDUSTRIES LTD. VALLOUREC MANNESMANN OIL & GAS FRANCE
Title of Invention:	Threaded Joint For Steel Pipes

Patent No.:	RE/R/2016/0019
Date of Grant:	10 June, 2011
Annuity:	8th Year
Applicant(s) / Proprietor(s):	THERACOS SUB, LLC
Title of Invention:	Crystalline Form Of Benzylbenzene Sgl2 Inhibitor

Patent No.:	RE/R/2017/0010
--------------------	-----------------------



Date of Grant:	7 July, 2015
Annuity:	7th Year
Applicant(s) / Proprietor(s):	SUMITOMO METAL INDUSTRIES LTD. VALLOUREC MANNESMANN OIL & GAS FRANCE
Title of Invention:	Photocurable Composition Suitable For Rust Prevention Of A Threaded Joint For Steel Pipes

Patent No.:	RE/R/2017/0012
Date of Grant:	22 June, 2016
Annuity:	7th Year
Applicant(s) / Proprietor(s):	ASTRAZENECA AB
Title of Invention:	Coated tablet formulation and method

Patent No.:	RE/R/2019/0003
Date of Grant:	26 July, 2018
Annuity:	5th Year
Applicant(s) / Proprietor(s):	EFFRX PHARMACEUTICALS SA
Title of Invention:	Stable Effervescent Bisphosphonate Formulations With Rapid Solubilization Characteristics

Patent No.:	RP/R/2009/0020
Date of Grant:	16 June, 2005
Annuity:	18th Year
Applicant(s) / Proprietor(s):	CHAMPION TECHNOLOGIES, INC
Title of Invention:	Low Dosage Naphthenate Inhibitors

Patent No.:	BN/N/2017/0086
--------------------	-----------------------



Date of Grant:	5 June, 2015
Annuity:	8th Year
Applicant(s) / Proprietor(s):	HALLIBURTON ENERGY SERVICES, INC.
Title of Invention:	Completion System For Gravel Packing With Zonal Isolation

Patent No.:	RE/R/2014/0068
Date of Grant:	4 June, 2014
Annuity:	9th Year
Applicant(s) / Proprietor(s):	ROYALTY PHARMA COLLECTION TRUST
Title of Invention:	Treatment of Type 2 Diabetes With a Combination of DPIV Inhibitor and Metformin or Thiazolidinedione

Patent No.:	RE/R/2012/0035
Date of Grant:	30 June, 2011
Annuity:	12th Year
Applicant(s) / Proprietor(s):	BOEHRINGER INGELHEIM INTERNATIONAL GMBH
Title of Invention:	DPP Iv Inhibitor Formulations

Patent No.:	RE/R/2013/0007
Date of Grant:	4 June, 2010
Annuity:	13th Year
Applicant(s) / Proprietor(s):	OPULENT ELECTRONICS INTERNATIONAL PTE LTD
Title of Invention:	Device And Method For Driving Leds

Patent No.:	RE/R/2014/0011
Date of Grant:	28 June, 2013



Annuity: 10th Year
Applicant(s) / Proprietor(s): SINGAPORE AIRLINES LIMITED
Title of Invention: Aircraft Seating And Seating Arrangements

Patent No.: RE/R/2014/0020
Date of Grant: 28 June, 2013
Annuity: 10th Year
Applicant(s) / Proprietor(s): INCYTE CORPORATION
Title of Invention: Azetidine And Cyclobutane Derivatives As Jak Inhibitors

Patent No.: RE/R/2015/0064
Date of Grant: 21 December, 2015
Annuity: 8th Year
Applicant(s) / Proprietor(s): Merus N.V.
Title of Invention: Antibody Producing Non-Human Mammals

Patent No.: RE/R/2016/0020
Date of Grant: 22 June, 2015
Annuity: 8th Year
Applicant(s) / Proprietor(s): REGENERON PHARMACEUTICALS, INC
Title of Invention: Stabilized Formulations Containing Anti-Ngf Antibodies

Patent No.: RE/R/2016/0023
Date of Grant: 26 June, 2015
Annuity: 8th Year
Applicant(s) / Proprietor(s): ELI LILLY AND COMPANY
Title of Invention: CGRP Antibodies



Patent No.:	RE/R/2017/0027
Date of Grant:	15 June, 2016
Annuity:	7th Year
Applicant(s) / Proprietor(s):	VALLOUREC MANNESMANN OIL & GAS FRANCE SUMITOMO METAL INDUSTRIES, LTD.
Title of Invention:	Threaded Connection Comprising At Least One Threaded Element With An End Lip For A Metal Tube
Patent No.:	RE/R/2017/0053
Date of Grant:	13 June 2017
Annuity:	6th Year
Applicant(s) / Proprietor(s):	METROL TECHNOLOGY LIMITED
Title of Invention:	Casing Valve
Patent No.:	RE/R/2017/0060
Date of Grant:	28 June, 2017
Annuity:	6th Year
Applicant(s) / Proprietor(s):	BAKER HUGHES INCORPORATED
Title of Invention:	Method Of Measuring Multi-Phase Fluid Flow Downhole
Patent No.:	RE/R/2018/0027
Date of Grant:	30 July, 2017
Annuity:	6th Year
Applicant(s) / Proprietor(s):	AMGEN K-A, INC.
Title of Invention:	Lyophilized Therapeutic Peptibody Formulations



Patent No.:	RP/R/2011/0029
Date of Grant:	15 June, 2011
Annuity:	12th Year
Applicant(s) / Proprietor(s):	Boehringer Ingelheim International GMBH
Title of Invention:	Uses Of Dpp-IV Inhibitors

Patent No.:	RE/R/2012/0040
Date of Grant:	16 June, 2005
Annuity:	17th Year
Applicant(s) / Proprietor(s):	Ronald Neville Langford
Title of Invention:	Authenticating Images Identified By A Software Application

Patent No.:	RE/R/2015/0042
Date of Grant:	09 July, 2014
Annuity:	7th Year
Applicant(s) / Proprietor(s):	ACCELERON PHARMA INC.
Title of Invention:	Variants Derived From Actriiib And Uses Therefor

Patent No.:	RP/R/2008/0067
Date of Grant:	29 June, 2007
Annuity:	16th Year
Applicant(s) / Proprietor(s):	SUMITOMO METAL INDUSTRIES, LTD. and VALLOUREC MANNESMANN OIL & GAS FRANCE
Title of Invention:	A Premium Threaded Turbular Connection Comprising At Least One Threaded Element With An End Lip



Patent No.:	BN/N/2014/0004
Date of Grant:	27 July, 2011
Annuity:	11th Year
Applicant(s) / Proprietor(s):	ASTRAZENECA AB
Title of Invention:	2 - (2, 4, 5 - Substituted -Anilino) Pyrimidine Derivatives As Egfr Modulators Useful For Treating Cancer

Patent No.:	BN/N/2017/0080
Date of Grant:	30 June, 2015
Annuity:	8th Year
Applicant(s) / Proprietor(s):	HALLIBURTON ENERGY SERVICES, INC
Title of Invention:	Outflow Control Device For Creating A Packer

Patent No.:	BN/N/2017/0104
Date of Grant:	01 July, 2016
Annuity:	7th Year
Applicant(s) / Proprietor(s):	AUDION THERAPEUTICS and ELI LILLY AND COMPANY
Title of Invention:	Notch Pathway Signaling Inhibitor Compounds

Patent No.:	BN/N/2018/0036
Date of Grant:	16 December, 2016
Annuity:	5th Year
Applicant(s) / Proprietor(s):	NIPPON STEEL & SUMITOMO METAL CORPORATION and VALLOUREC MANNESMANN OIL & GAS FRANCE
Title of Invention:	Method Of Producing The Threaded Connection For Pipe Or Tube



Patent No.: BN/N/2018/0036
Date of Grant: 16 December, 2016
Annuity: 6th Year
Applicant(s) / Proprietor(s): NIPPON STEEL & SUMITOMO METAL CORPORATION VALLOUREC MANNESMANN OIL & GAS FRANCE
Title of Invention: Method Of Producing The Threaded Connection For Pipe Or Tube

Patent No.: BN/N/2018/0036
Date of Grant: 16 December, 2016
Annuity: 7th Year
Applicant(s) / Proprietor(s): NIPPON STEEL & SUMITOMO METAL CORPORATION VALLOUREC MANNESMANN OIL & GAS FRANCE
Title of Invention: Method Of Producing The Threaded Connection For Pipe Or Tube

Patent No.: BN/N/2020/0002
Date of Grant: 02 July, 2018
Annuity: 5th Year
Applicant(s) / Proprietor(s): GP NETWORK ASIA PTE. LTD.
Title of Invention: Processing Payments

Patent No.: RE/R/2013/0059
Date of Grant: 31 July, 2012
Annuity: 11th Year
Applicant(s) / Proprietor(s): PIERRE FABRE MEDICAMENT



Title of Invention: Novel Antibodies Inhibiting C-Met Dimerization, And Uses Thereof

Patent No.: RE/R/2015/0042

Date of Grant: 31 July, 2012

Annuity: 8th Year

Applicant(s) / Proprietor(s): ACCELERON PHARMA INC.

Title of Invention: Variants Derived From Actriib And Uses Therefor

Patent No.: RE/R/2015/0042

Date of Grant: 31 July, 2012

Annuity: 9th Year

Applicant(s) / Proprietor(s): ACCELERON PHARMA INC.

Title of Invention: Variants Derived From Actriib And Uses Therefor

Patent No.: RE/R/2015/0054

Date of Grant: 06 July, 2007

Annuity: 16th Year

Applicant(s) / Proprietor(s): GILEAD SCIENCES, INC.

Title of Invention: Modulators Of Pharmacokinetic Properties Of Therapeutics

Patent No.: RE/R/2016/0024

Date of Grant: 08 July, 2015

Annuity: 8th Year

Applicant(s) / Proprietor(s): HUTCHISON MEDIPHARMA LIMITED

Title of Invention: Certain Triazolopyrazines, Compositions Thereof And



Methods Of Use Therefor

Patent No.:	RE/R/2017/0021
Date of Grant:	06 July, 2016
Annuity:	7th Year
Applicant(s) / Proprietor(s):	PEARL THERAPEUTICS, INC.
Title of Invention:	Compositions For Respiratory Delivery Of Active Agents And Associated Methods And Systems

Patent No.:	RE/R/2017/0022
Date of Grant:	06 July, 2016
Annuity:	7th Year
Applicant(s) / Proprietor(s):	PEARL THERAPEUTICS, INC.
Title of Invention:	Respiratory Delivery Of Active Agents

Patent No.:	RE/R/2017/0023
Date of Grant:	06 July, 2016
Annuity:	7th Year
Applicant(s) / Proprietor(s):	PEARL THERAPEUTICS, INC.
Title of Invention:	Compositions For Pulmonary Delivery Of Long-Acting Muscarinic Antagonists And Long-Acting B2 Adrenergic Receptor Agonists And Associated Methods And Systems

Patent No.:	RE/R/2017/0030
Date of Grant:	08 July, 2016
Annuity:	7th Year
Applicant(s) / Proprietor(s):	GILEAD SCIENCES, INC. JAPAN TOBACCO, INC.



Title of Invention: Methods For Improving The Pharmacokinetics Of Hiv Integrase Inhibitors

Patent No.: RE/R/2018/0018

Date of Grant: 14 July, 2017

Annuity: 6th Year

Applicant(s) / Proprietor(s): MITSUBISHI GAS CHEMICAL COMPANY, INC.

Title of Invention: Methanol Synthesis Catalyst

Patent No.: RE/R/2018/0029

Date of Grant: 07 December, 2009

Annuity: 14th Year

Applicant(s) / Proprietor(s): GILEAD SCIENCES, INC.

Title of Invention: Modulators Of Toll-Like Receptors

Patent No.: RP/R/2008/0003

Date of Grant: 31 May, 2006

Annuity: 17th Year

Applicant(s) / Proprietor(s): Novartis AG

Title of Invention: N-(Substituted Glycyl)-2-Cyanopyrrolidines, Pharmaceutical Compositions Containing Them And Their Use In Inhibiting Dipeptidyl Peptidase -Iv

Patent No.: RP/R/2008/0024

Date of Grant: 11 July, 2007

Annuity: 16th Year

Applicant(s) / Proprietor(s): Bavarian Nordic A/S

Title of Invention: Modified Vaccinia Virus Ankara For The Vaccination Of



Neonates

Patent No.:	BN/N/2015/0004
Date of Grant:	09 August 2012
Annuity:	10th Year
Applicant(s) / Proprietor(s):	SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B. V
Title of Invention:	Process For Producing And Separating Oil

Patent No.:	BN/N/2016/0004
Date of Grant:	01 August, 2014
Annuity:	9th Year
Applicant(s) / Proprietor(s):	LIQWD, INC.
Title of Invention:	Methods For Fixing Hair And Skin

Patent No.:	BN/N/2018/0008
Date of Grant:	31 July, 2015
Annuity:	8th Year
Applicant(s) / Proprietor(s):	AKESO BIOPHARMA, INC.
Title of Invention:	An Anti-Ctla4 Monoclonal Antibody Or Antigen Binding Fragment Thereof, A Pharmaceutical Composition And Use

Patent No.:	RE/R/2015/0045
Date of Grant:	13 August, 2014
Annuity:	9th Year
Applicant(s) / Proprietor(s):	ASTRAZENECA AB
Title of Invention:	Morpholino Pyrimidines And Their Use In Therapy



Patent No.:	RE/R/2016/0022
Date of Grant:	08 July, 2015
Annuity:	8th Year
Applicant(s) / Proprietor(s):	SUMITOMO METAL INDUSTRIES, LTD. VALLOUREC MANNESMANN OIL & GAS FRANCE
Title of Invention:	Threaded Joint For Steel Pipes

Patent No.:	RE/R/2016/0026
Date of Grant:	19 August, 2015
Annuity:	8th Year
Applicant(s) / Proprietor(s):	GILEAD PHARMASSET LLC
Title of Invention:	Antiviral Compounds

Patent No.:	RE/R/2016/0029
Date of Grant:	10 July, 2015
Annuity:	8th Year
Applicant(s) / Proprietor(s):	SKYONIC CORPORATION
Title of Invention:	Carbon Dioxide Sequestrations Involving Two-Salt-Based Thermolytic Processes

Patent No.:	RE/R/2017/0031
Date of Grant:	20 July, 2016
Annuity:	7th Year
Applicant(s) / Proprietor(s):	KUDOS PHARMACEUTICALS LIMITED
Title of Invention:	Pharmaceutical Formulation 514



Patent No.:	RE/R/2017/0046
Date of Grant:	09 August, 2017
Annuity:	6th Year
Applicant(s) / Proprietor(s):	MEDIMMUNE LIMITED
Title of Invention:	Targeted Binding Agents Against B7-H1

Patent No.:	RP/R/2004/0028
Date of Grant:	28 October, 1999
Annuity:	20th Year
Applicant(s) / Proprietor(s):	SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V.
Title of Invention:	Method For Transporting And Installing An Expandable Steel Tubular

Patent No.:	RP/R/2011/0025
Date of Grant:	30 July, 2010
Annuity:	13th Year
Applicant(s) / Proprietor(s):	SUMITOMO METAL INDUSTRIES, LTD. and VALLOUREC MANNESMANN OIL & GAS FRANCE
Title of Invention:	Lubricating Coating Composition Suitable For Lubrication Of A Threaded Joint

Patent No.:	RP/R/2011/0051
Date of Grant:	24 August, 2011
Annuity:	12th Year
Applicant(s) / Proprietor(s):	Shell Internationale Research Maatschappij B. V.
Title of Invention:	Marine Time Lapse Seismic Surveying



Patent No.: BN/N/2016/0001
Date of Grant: 03 July, 2014
Annuity: 9th Year
Applicant(s) / Proprietor(s): PIONEER LINING TECHNOLOGY LIMITED
Title of Invention: Improved Electrofusion Fitting Methods

Patent No.: BN/N/2017/0002
Date of Grant: 24 July, 2015
Annuity: 8th Year
Applicant(s) / Proprietor(s): ASTRAZENECA AB
Title of Invention: [1,2,4] Triazolo [4,3-B] Pyridazines For Use In The Treatment Of Proliferative Diseases

Patent No.: BN/N/2020/0001
Date of Grant: 02 July, 2018
Annuity: 5th Year
Applicant(s) / Proprietor(s): GP NETWORK ASIA PTE. LTD.
Title of Invention: Processing Payments

Patent No.: RE/R/2017/0037
Date of Grant: 27 July, 2016
Annuity: 7th Year
Applicant(s) / Proprietor(s): WYETH HOLDINGS LLC
Title of Invention: Calicheamicin Derivative-Carrier Conjugates

Patent No.: RE/R/2018/0023



Date of Grant: 30 June, 2017
Annuity: 6th Year
Applicant(s) / Proprietor(s): MATSUMOTO SYSTEM ENGINEERING CO., LTD.
Title of Invention: Grapple Bucket Apparatus

Patent No.: RE/R/2019/0006
Date of Grant: 11 July, 2018
Annuity: 5th Year
Applicant(s) / Proprietor(s): CUBIST PHARMACEUTICALS LLC
Title of Invention: Lipopeptide Compositions And Related Methods

Patent No.: BN/N/2015/0130
Date of Grant: 08 August, 2013
Annuity: 10th Year
Applicant(s) / Proprietor(s): SAFWAY SERVICES, LLC
Title of Invention: Access Structure Integration Assembly And Integrated Access Systems And Methods Of Using The Same

Patent No.: RE/R/2012/0061
Date of Grant: 29 July, 2011
Annuity: 12th Year
Applicant(s) / Proprietor(s): HELSINN HEALTHCARE SA
Title of Invention: Liquid Pharmaceutical Formulations Of Palonosetron

Patent No.: RE/R/2015/0023
Date of Grant: 31 July, 2014
Annuity: 9th Year



Applicant(s) / Proprietor(s): HALLIBURTON ENERGY SERVICES, INC.
Title of Invention: Treatment Fluids Comprising Relative Permeability Modifiers And Methods Of Use

Patent No.: RE/R/2015/0047
Date of Grant: 31 July, 2014
Annuity: 9th Year

Applicant(s) / Proprietor(s): OIL STATES INTERNATIONAL
Title of Invention: Two-Element Tandem Flexible Joint

Patent No.: RE/R/2015/0070
Date of Grant: 12 August, 2015
Annuity: 8th Year

Applicant(s) / Proprietor(s): ALMIRALL, S.A.
Title of Invention: Inhalation Composition Containing Aclidinium For Treatment Of Chronic Obstructive Pulmonary Disease

Patent No.: RE/R/2016/0012
Date of Grant: 08 July, 2015
Annuity: 8th Year

Applicant(s) / Proprietor(s): WYETH HOLDINGS LLC
Title of Invention: Calicheamicin Derivative-Carrier Conjugates

Patent No.: RE/R/2016/0030
Date of Grant: 13 July, 2015
Annuity: 8th Year

Applicant(s) / Proprietor(s): METROL TECHNOLOGY LIMITED



Title of Invention: A Safety Mechanism For A Well, A Well Comprising The Safety Mechanism, And Related Methods

Patent No.: RE/R/2017/0029

Date of Grant: 06 July, 2016

Annuity: 7th Year

Applicant(s) / Proprietor(s): EISAI R&D MANAGEMENT CO., LTD.

Title of Invention: Liposome Composition

Patent No.: BN/N/2018/0115

Date of Grant: 14 November, 2016

Annuity: 5th Year

Applicant(s) / Proprietor(s): HALLIBURTON ENERGY SERVICES, INC.

Title of Invention: Shunt System For Downhole Sand Control Completions

Patent No.: BN/N/2018/0115

Date of Grant: 14 November, 2016

Annuity: 6th Year

Applicant(s) / Proprietor(s): HALLIBURTON ENERGY SERVICES, INC.

Title of Invention: Shunt System For Downhole Sand Control Completions

Patent No.: BN/N/2019/0060

Date of Grant: 27 December, 2016

Annuity: 6th Year

Applicant(s) / Proprietor(s): HALLIBURTON ENERGY SERVICES, INC.

Title of Invention: Flow Control Devices With Pressure-Balanced Pistons



Patent No.:	BN/N/2019/0060
Date of Grant:	21 May, 2022
Annuity:	5th Year
Applicant(s) / Proprietor(s):	HALLIBURTON ENERGY SERVICES, INC.
Title of Invention:	Flow Control Devices With Pressure-Balanced Pistons

Patent No.:	RE/R/2013/0017
Date of Grant:	11 July, 2007
Annuity:	14th Year
Applicant(s) / Proprietor(s):	THOMSON LICENSING
Title of Invention:	Method For Representing Animated Menu Buttons

Patent No.:	RE/R/2017/0011
Date of Grant:	26 February, 2016
Annuity:	7th Year
Applicant(s) / Proprietor(s):	TAKEDA VACCINES, INC.
Title of Invention:	Methods And Compositions For Live Attenuated Viruses

Patent No.:	RE/R/2013/0077
Date of Grant:	24 May, 2006
Annuity:	14th Year
Applicant(s) / Proprietor(s):	FIRST DATA CORPORATION
Title of Invention:	Transaction Instruments With Enhanced Security Pin And Expiration Date Generation



Patent No.: RP/R/2008/0044
Date of Grant: 24 May, 2001
Annuity: 20th Year
Applicant(s) / Proprietor(s): NOVARTIS AG
Title of Invention: Thrombopoietin Mimetics

Patent No.: BN/N/2018/0016
Date of Grant: 21 October, 2016
Annuity: 5th Year
Applicant(s) / Proprietor(s): NANYANG TECHNOLOGICAL UNIVERSITY and PROGEN PTE LTD
Title of Invention: Passive Chilled Panel

Patent No.: BN/N/2018/0073
Date of Grant: 02 February, 2017
Annuity: 5th Year
Applicant(s) / Proprietor(s): AMGEN RESEARCH (MUNICH) GMBH
Title of Invention: Bispecific T Cell Engaging Antibody Constructs

Patent No.: BN/N/2018/0073
Date of Grant: 02 February, 2017
Annuity: 6th Year
Applicant(s) / Proprietor(s): AMGEN RESEARCH (MUNICH) GMBH
Title of Invention: Bispecific T Cell Engaging Antibody Constructs

Patent No.: RP/R/2002/0011
Date of Grant: 21 November, 2001



Annuity: 20th Year

Applicant(s) / Proprietor(s): SHELL INTERNATIONALE MAATSCHAPPIJ B.V. RESEARCH

Title of Invention: Deformable Well Screen And Method For Its Installation

Patent No.: RP/R/2005/0003

Date of Grant: 31 October, 2002

Annuity: 19th Year

Applicant(s) / Proprietor(s): JANSSEN PHARMACEUTICA N.V.

Title of Invention: Farnesyl Protein Transferase Inhibiting (Imidazol-5-Yl) Methyl -2-Quinolinone Derivatives

Patent No.: BN/N/2019/0081

Date of Grant: 19 December, 2017

Annuity: 5th Year

Applicant(s) / Proprietor(s): ASTRAZENECA UK LIMITED

Title of Invention: Amino-Triazolopyridine Compounds And Their Use In Treating Cancer

Patent No.: RE/R/2016/0027

Date of Grant: 25 April, 2016

Annuity: 7th Year

Applicant(s) / Proprietor(s): CRYSTAL LAGOONS (CURACAO) B.V.

Title of Invention: Method And System For Treating Water Used For Industrial Purposes

Patent No.: BN/N/2016/0005

Date of Grant: 04 August, 2014

Annuity: 9th Year



Applicant(s) / Proprietor(s):	KOURIS, PAUL, STEVEN
Title of Invention:	An Assembly For Generating Electricity
<hr/>	<hr/>
Patent No.:	BN/N/2016/0023
Date of Grant:	19 December, 2013
Annuity:	5th Year
Applicant(s) / Proprietor(s):	HALLIBURTON ENERGY SERVICES, INC.
Title of Invention:	Intervention Tool For Delivering Self-Assembling Repair Fluid
<hr/>	<hr/>
Patent No.:	RE/R/2012/0049
Date of Grant:	29 August, 2006
Annuity:	17th Year
Applicant(s) / Proprietor(s):	TAKEDA PHARMACEUTICAL COMPANY LIMITED
Title of Invention:	1 - Heterocyclsulfonyl, 2 - Aminomethyl, 5 - (Hetero -) Aryl Substituted 1 - H - Pyrrole Derivatives As Acid Secretion Inhibitors
<hr/>	<hr/>
Patent No.:	RE/R/2013/0033
Date of Grant:	29 August, 2012
Annuity:	11th Year
Applicant(s) / Proprietor(s):	MERCK SHARP & DOHME CORP. MSD ITALIA S.R.L.
Title of Invention:	Macrocyclic Quinoxaline Compounds As Hcv Ns3 Protease Inhibitors
<hr/>	<hr/>
Patent No.:	RE/R/2013/0062
Date of Grant:	24 August, 2007
Annuity:	16th Year



Applicant(s) / Proprietor(s): PURDUE PHARMA L.P.
Title of Invention: Tamper Resistant Oral Pharmaceutical Dosage Forms Comprising An Opioid Analgesic

Patent No.: RE/R/2013/0065
Date of Grant: 17 August, 2006
Annuity: 17th Year
Applicant(s) / Proprietor(s): ARRAY BIOPHARMA, INC.
Title of Invention: 8-Substituted Benzoazepines As Toll-Like Receptor Modulators

Patent No.: RE/R/2013/0067
Date of Grant: 29 August, 2008
Annuity: 15th Year
Applicant(s) / Proprietor(s): PURDUE PHARMA L.P.
Title of Invention: Substituted-Quinoxaline-Type-Piperidine Compounds And The Uses Thereof

Patent No.: RE/R/2016/0034
Date of Grant: 08 July, 2015
Annuity: 8th Year
Applicant(s) / Proprietor(s): ESTEVE PHARMACEUTICALS, S.A.
Title of Invention: Pharmaceutical Compositions Of Co-Crystals Of Tramadol And Coxibs

Patent No.: RE/R/2017/0041
Date of Grant: 23 August, 2016
Annuity: 7th Year



Applicant(s) / Proprietor(s): IMMUNOGEN, INC.
Title of Invention: Folate Receptor 1 Antibodies And Immunoconjugates And Uses Thereof

Patent No.: RE/R/2019/0010
Date of Grant: 22 August, 2018
Annuity: 5th Year
Applicant(s) / Proprietor(s): VIV HEALTHCARE COMPANY
Title of Invention: Antiviral Therapy

Patent No.: BN/N/2015/0093
Date of Grant: 11 August, 2015
Annuity: 8th Year
Applicant(s) / Proprietor(s): UNIVERSITI BRUNEI DARUSSALAM
Title of Invention: A Method To Enhance The Efficiency Of Dye Sensitized And Perovskite Solar Cell

Patent No.: BN/N/2016/0006
Date of Grant: 05 August, 2014
Annuity: 9th Year
Applicant(s) / Proprietor(s): CHIYODA CORPORATION
Title of Invention: Hydrogen Supply System And Hydrogen Supply Method

Patent No.: BN/N/2018/0007
Date of Grant: 29 August, 2016
Annuity: 7th Year
Applicant(s) / Proprietor(s): MEDRX CO. LTD.



Title of Invention: Transdermally Absorptive Composition

Patent No.: BN/N/2018/0018

Date of Grant: 15 September, 2016

Annuity: 7th Year

Applicant(s) / Proprietor(s): ASTRAZENECA AB

Title of Invention: 8-[6-[3-(Amino)Propoxy]-3-Pyridyl]-1 -Isopropyl-
Imidazo[4,5-C]Quinolin-2-One Derivatives As Selective
Modulators Of Ataxia Telangiectasia Mutated (Atm)
Kinase For The Treatment Of Cancer

Patent No.: BN/N/2018/0022

Date of Grant: 15 September, 2016

Annuity: 6th Year

Applicant(s) / Proprietor(s): ASSEMBLY BIOSCIENCES, INC.
INDIANA UNIVERSITY RESEARCH AND
TECHNOLOGY CORPORATION

Title of Invention: Hepatitis B Core Protein Modulators

Patent No.: BN/N/2018/0022

Date of Grant: 15 September, 2016

Annuity: 5th Year

Applicant(s) / Proprietor(s): ASSEMBLY BIOSCIENCES, INC.
INDIANA UNIVERSITY RESEARCH AND
TECHNOLOGY CORPORATION

Title of Invention: Hepatitis B Core Protein Modulators

Patent No.: BN/N/2018/0070

Date of Grant: 10 February, 2017

Annuity: 6th Year



Applicant(s) / Proprietor(s): ASTRAZENECA AB and
EOLAS THERAPEUTICS, INC.

Title of Invention: Halo-Substituted Piperidines As Orexin Receptor Modulators

Patent No.: BN/N/2018/0070

Date of Grant: 10 February, 2017

Annuity: 6th Year

Applicant(s) / Proprietor(s): ASTRAZENECA AB
EOLAS THERAPEUTICS, INC.

Title of Invention: Halo-Substituted Piperidines As Orexin Receptor Modulators

Patent No.: BN/N/2018/0101

Date of Grant: 05 May, 2017

Annuity: 6th Year

Applicant(s) / Proprietor(s): BISN TEC LTD

Title of Invention: Chemical Heat Sources For Use In Down-Hole Operations

Patent No.: BN/N/2019/0013

Date of Grant: 21 June, 2017

Annuity: 6th Year

Applicant(s) / Proprietor(s): AVASURE, LLC

Title of Invention: Video Load Balancing System For A Peer-To-Peer Server Network

Patent No.: RE/R/2013/0090

Date of Grant: 31 August, 2013

Annuity: 10th Year



Applicant(s) / Proprietor(s): BOEHRINGER INGELHEIM INTERNATIONAL GMBH
Title of Invention: Treatment For Diabetes In Patients Inappropriate For Metformin Therapy

Patent No.: RE/R/2015/0014
Date of Grant: 14 May, 2014
Annuity: 9th Year

Applicant(s) / Proprietor(s): TOTAL S.A.
Title of Invention: Pipe For Transporting A Fluid Containing A Hydrocarbon, And Method For Producing Such A Line

Patent No.: RE/R/2015/0034
Date of Grant: 13 August, 2014
Annuity: 9th Year

Applicant(s) / Proprietor(s): BIOGEN MA INC.
Title of Invention: Heterocyclic sulfonamides, uses and pharmaceutical compositions thereof

Patent No.: RE/R/2017/0026
Date of Grant: 30 August, 2016
Annuity: 7th Year

Applicant(s) / Proprietor(s): GLAXOSMITHKLINE LLC
Title of Invention: Novel Pharmaceutical Composition

Patent No.: RE/R/2017/0054
Date of Grant: 04 August, 2017
Annuity: 6th Year

Applicant(s) / Proprietor(s): METROL TECHNOLOGY LIMITED



Title of Invention: A Well Comprising A Safety Mechanism And Sensors

Patent No.: RE/R/2018/0024

Date of Grant: 21 June, 2017

Annuity: 6th Year

Applicant(s) / Proprietor(s): ANACOR PHARMACEUTICALS, INC.

Title of Invention: Benzoxaborole Derivatives For Treating Bacterial Infections

Patent No.: RE/R/2018/0028

Date of Grant: 02 August, 2017

Annuity: 6th Year

Applicant(s) / Proprietor(s): HOSPIRA, INC.

Title of Invention: Spray Drying Vancomycin

Patent No.: RE/R/2019/0007

Date of Grant: 14 August, 2018

Annuity: 5th Year

Applicant(s) / Proprietor(s): IMPACT BIOMEDICINES, INC.

Title of Invention: Bi-Aryl Meta-Pyrimidine Inhibitors Of Kinases

Patent No.: RP/R/2005/0002

Date of Grant: 30 August, 2004

Annuity: 19th Year

Applicant(s) / Proprietor(s): JANSSEN PHARMACEUTICA N.V.

Title of Invention: Aqueous Suspensions Of Submicron 9-Hydroxyrisperidone Fatty Acid Esters



Patent No.:	RP/R/2005/0006
Date of Grant:	01 September, 2004
Annuity:	19th Year
Applicant(s) / Proprietor(s):	SHELL INTERNATIONALE MAATSCHAPPIJ B.V. RESEARCH
Title of Invention:	Method For Annular Sealing

Patent No.:	RP/R/2010/0041
Date of Grant:	5 August, 2009
Annuity:	14th Year
Applicant(s) / Proprietor(s):	MERCK SHARP & DOHME CORP.
Title of Invention:	Pharmaceutical Composition Containing Proton Pump Inhibitors

Patent No.:	RP/R/2011/0047
Date of Grant:	01 September, 2006
Annuity:	17th Year
Applicant(s) / Proprietor(s):	PFIZER LIMITED
Title of Invention:	Carboxamide Derivatives As Muscarinic Receptor Antagonists

Patent No.:	BN/N/2015/0119
Date of Grant:	05 November, 2015
Annuity:	8th Year
Applicant(s) / Proprietor(s):	WCM OIL & GAS SDN BHD
Title of Invention:	Welding Isolation Chamber Habitat System



Patent No.: BN/N/2016/0048
Date of Grant: 02 January, 2015
Annuity: 5th Year
Applicant(s) / Proprietor(s): ASTRAZENECA AB
Title of Invention: Pharmaceutical Compositions Comprising Azd9291

Patent No.: BN/N/2016/0048
Date of Grant: 02 January, 2015
Annuity: 6th Year
Applicant(s) / Proprietor(s): ASTRAZENECA AB
Title of Invention: Pharmaceutical Compositions Comprising Azd9291

Patent No.: BN/N/2016/0048
Date of Grant: 02 January, 2015
Annuity: 7th Year
Applicant(s) / Proprietor(s): ASTRAZENECA AB
Title of Invention: Pharmaceutical Compositions Comprising Azd9291

Patent No.: BN/N/2016/0048
Date of Grant: 02 January, 2015
Annuity: 8th Year
Applicant(s) / Proprietor(s): ASTRAZENECA AB
Title of Invention: Pharmaceutical Compositions Comprising Azd9291

Patent No.: RE/R/2016/0036



Date of Grant:	13 May, 2016
Annuity:	7th Year
Applicant(s) / Proprietor(s):	DOLBY INTERNATIONAL AB DOLBY LABORATORIES LICENSING CORPORATION
Title of Invention:	Audio Decoder And Decoding Method Using Efficient Downmixing

Patent No.:	BN/N/2016/0024
Date of Grant:	12 September, 2014
Annuity:	6th Year
Applicant(s) / Proprietor(s):	ASTRAZENECA AB
Title of Invention:	Therapeutic Polymeric Nanoparticles And Methods Of Making And Using Same

Patent No.:	BN/N/2016/0024
Date of Grant:	12 September, 2014
Annuity:	7th Year
Applicant(s) / Proprietor(s):	ASTRAZENECA AB
Title of Invention:	Therapeutic Polymeric Nanoparticles And Methods Of Making And Using Same

Patent No.:	BN/N/2016/0024
Date of Grant:	12 September, 2014
Annuity:	8th Year
Applicant(s) / Proprietor(s):	ASTRAZENECA AB
Title of Invention:	Therapeutic Polymeric Nanoparticles And Methods Of Making And Using Same



Date of Grant: 12 September, 2014
Annuity: 5th Year
Applicant(s) / Proprietor(s): ASTRAZENECA AB
Title of Invention: Therapeutic Polymeric Nanoparticles And Methods Of Making And Using Same

Patent No.: BN/N/2015/0017
Date of Grant: 26 September, 2012
Annuity: 11th Year
Applicant(s) / Proprietor(s): HALLIBURTON ENERGY SERVICES, INC.
Title of Invention: Single Trip Multi-Zone Completion Systems And Methods

Patent No.: BN/N/2015/0021
Date of Grant: 26 September, 2012
Annuity: 11th Year
Applicant(s) / Proprietor(s): HALLIBURTON ENERGY SERVICES, INC.
Title of Invention: Tubing Conveyed Multiple Zone Integrated Intelligent Well Completion

Patent No.: BN/N/2015/0027
Date of Grant: 26 September, 2012
Annuity: 11th Year
Applicant(s) / Proprietor(s): HALLIBURTON ENERGY SERVICES, INC.
Title of Invention: Completion Assembly And Methods For Use Thereof

Patent No.: BN/N/2015/0030
Date of Grant: 26 September, 2012



Annuity: 11th Year
Applicant(s) / Proprietor(s): HALLIBURTON ENERGY SERVICES, INC.
Title of Invention: Single Trip Multi-Zone Completion Systems And Methods

Patent No.: BN/N/2018/0023
Date of Grant: 30 August, 2016
Annuity: 7th Year
Applicant(s) / Proprietor(s): PIPELIFE NEDERLAND B.V.
Title of Invention: High Pressure Pipe And Method For Producing Such Pipe

Patent No.: BN/N/2018/0023
Date of Grant: 30 August, 2016
Annuity: 5th Year
Applicant(s) / Proprietor(s): PIPELIFE NEDERLAND B.V.
Title of Invention: High Pressure Pipe And Method For Producing Such Pipe

Patent No.: BN/N/2018/0023
Date of Grant: 30 August, 2016
Annuity: 6th Year
Applicant(s) / Proprietor(s): PIPELIFE NEDERLAND B.V.
Title of Invention: High Pressure Pipe And Method For Producing Such Pipe

Patent No.: BN/N/2018/0115
Date of Grant: 14 November, 2016
Annuity: 7th Year
Applicant(s) / Proprietor(s): HALLIBURTON ENERGY SERVICES, INC.



Title of Invention: Shunt System For Downhole Sand Control Completions

Patent No.: RE/R/2012/0022

Date of Grant: 13 September, 2006

Annuity: 17th Year

Applicant(s) / Proprietor(s): Takeda Pharmaceutical Company Limited

Title of Invention: Dipeptidyl Peptidase Inhibitors For Treating Diabetes

Patent No.: RE/R/2018/0037

Date of Grant: 18 July, 2018

Annuity: 5th Year

Applicant(s) / Proprietor(s): NIPPON STEEL & SUMITOMO METAL CORPORATION
VALLOUREC OIL AND GAS FRANCE

Title of Invention: Method And Device For Inspecting A Threading Of A Tubular Connection Used In The Oil Industry

Patent No.: RP/R/2011/0041

Date of Grant: 29 August, 2006

Annuity: 17th Year

Applicant(s) / Proprietor(s): TAKEDA PHARMACEUTICAL COMPANY LIMITED

Title of Invention: 1-Heterocyclsulfonyl, 2-Aminomethyl, 5- (Hetero-) Aryl Substituted 1-H-Pyrrole Derivatives As Acid Secretion Inhibitors

Patent No.: BN/N/2015/0010

Date of Grant: 11 September, 2013

Annuity: 10th Year



Applicant(s) / Proprietor(s): NIPPON STEEL & SUMITOMO METAL
CORPORATION
VALLOUREC OIL AND GAS FRANCE

Title of Invention: Threaded Joint For Steel Pipe

Patent No.: BN/N/2017/0019

Date of Grant: 08 September, 2015

Annuity: 8th Year

Applicant(s) / Proprietor(s): ELI LILLY AND COMPANY

Title of Invention: Treatment Of Androgen Deprivation Therapy Associated Symptoms

Patent No.: BN/N/2018/0104

Date of Grant: 16 September, 2016

Annuity: 6th Year

Applicant(s) / Proprietor(s): NIPPON STEEL & SUMITOMO METAL
CORPORATION
VALLOUREC OIL AND GAS FRANCE

Title of Invention: Threaded Connection

Patent No.: RE/R/2012/0016

Date of Grant: 11 September, 2007

Annuity: 16th Year

Applicant(s) / Proprietor(s): TAKEDA PHARMACEUTICAL COMPANY LIMITED

Title of Invention: 2-6-(3-Amino-Piperidin-1-Yl)-3-Methyl-2, 4-Dioxo-3, 4-Dihydro-2h-Pyrimidin-1-Ylmethyl-4-Fluoro-Benzonitrile
For Treating Diabetes, Cancer, Autoimmune Disorders And Hiv Infection

Patent No.: RE/R/2014/0055



Date of Grant:	30 September, 2011
Annuity:	12th Year
Applicant(s) / Proprietor(s):	NOVARTIS AG
Title of Invention:	Combination Of Glycopyrrolate And Beta2 Adrenoceptor Agonists

Patent No.:	RE/R/2018/0026
Date of Grant:	31 July, 2017
Annuity:	6th Year
Applicant(s) / Proprietor(s):	KUDOS PHARMACEUTICALS LIMITED
Title of Invention:	Phthalazinone
	Derivative

Patent No.:	BN/N/2020/0023
Date of Grant:	26 September, 2018
Annuity:	5th Year
Applicant(s) / Proprietor(s):	INCYTE CORPORATION
Title of Invention:	Salts Of Pyrrolotriazine Derivatives Useful As Tam Inhibitors

Patent No.:	RE/R/2012/0006
Date of Grant:	15 September, 2011
Annuity:	12th Year
Applicant(s) / Proprietor(s):	BOEHRINGER INGELHEIM INTERNATIONAL GMBH
Title of Invention:	Polymorphs

Patent No.:	RE/R/2013/0081
Date of Grant:	6 July, 2009



Annuity: 11th Year
Applicant(s) / Proprietor(s): HOUSING AND DEVELOPMENT BOARD
Title of Invention: A Plant Tray

Patent No.: RE/R/2017/0019
Date of Grant: 28 September, 2016
Annuity: 7th Year
Applicant(s) / Proprietor(s): MSD K.K.
Title of Invention: Bicycloaniline Derivative

Patent No.: RE/R/2018/0012
Date of Grant: 04 October, 2017
Annuity: 6th Year
Applicant(s) / Proprietor(s): FLEXSTEEL PIPELINE TECHNOLOGIES, INC.
Title of Invention: Flexible Pipe Joint

Patent No.: RE/R/2018/0030
Date of Grant: 15 August, 2017
Annuity: 6th Year
Applicant(s) / Proprietor(s): AMGEN RESEARCH (MUNICH) GMBH
Title of Invention: Means And Methods For Treating Diblcl

Patent No.: RE/R/2019/0011
Date of Grant: 26 September, 2018
Annuity: 5th Year
Applicant(s) / Proprietor(s): ALKAHEST, INC.



Title of Invention: Co-Crystals And Salts Of Ccr3-Inhibitors

Patent No.: RP/R/2006/0014

Date of Grant: 01 October, 2003

Annuity: 20th Year

Applicant(s) / Proprietor(s): NOVARTIS AG

Title of Invention: Crystal Modification Of A N-Phenyl-2-Pyrimidineamine Derivative, Processes For Its Manufacture And Its Use

Patent No.: BN/N/2017/0035

Date of Grant: 09 November, 2015

Annuity: 8th Year

Applicant(s) / Proprietor(s): MEDIMMUNE LIMITED

Title of Invention: Binding Molecules Specific For Cd73 And Uses Thereof

Patent No.: BN/N/2020/0012

Date of Grant: 06 November, 2018

Annuity: 5th Year

Applicant(s) / Proprietor(s): NIPPON STEEL CORPORATION AND VALLOUREC OIL AND GAS FRANCE

Title of Invention: Threaded Connection For Steel Pipe

Patent No.: RE/R/2016/0049

Date of Grant: 30 December, 2016

Annuity: 7th Year

Applicant(s) / Proprietor(s): JANSSEN SCIENCES IRELAND UC

Title of Invention: Aqueous Suspensions Of Tmc278



Patent No.: RE/R/2017/0056
Date of Grant: 31 October, 2016
Annuity: 5th Year
Applicant(s) / Proprietor(s): IMMUNOGEN, INC.
Title of Invention: Cross-Linkers And Their Uses

Patent No.: RE/R/2018/0035
Date of Grant: 18 October, 2017
Annuity: 6th Year
Applicant(s) / Proprietor(s): ASTRAZENECA AB
Title of Invention: N-Acylsulfonamide Apoptosis Promoters

Patent No.: RP/R/2009/0017
Date of Grant: 31 October, 2007
Annuity: 16th Year
Applicant(s) / Proprietor(s): JANSSEN ALZHEIMER IMMUNOTHERAPY
Title of Invention: Prevention And Treatment Of Amyloidogenic Disease

Patent No.: RP/R/2009/0021
Date of Grant: 08 October, 2008
Annuity: 15th Year
Applicant(s) / Proprietor(s): SHELL INTERNATIONALE RESEARCH
MAATSCHAPPIJ B.V.
Title of Invention: Borehole Imaging

Patent No.: RP/R/2009/0037



Date of Grant:	07 October, 2009
Annuity:	14th Year
Applicant(s) / Proprietor(s):	SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B. V
Title of Invention:	Method For Optimising The Production Of A Cluster Of Wells

Patent No.:	BN/N/2016/0024
Date of Grant:	12 September, 2014
Annuity:	9th Year
Applicant(s) / Proprietor(s):	ASTRAZENECA AB
Title of Invention:	Therapeutic Polymeric Nanoparticles And Methods Of Making And Using Same

Patent No.:	BN/N/2016/0028
Date of Grant:	10 October, 2014
Annuity:	9th Year
Applicant(s) / Proprietor(s):	BERLIN-CHEMIE AG
Title of Invention:	Conjugated Antibodies Against Ly75 For The Treatment Of Cancer

Patent No.:	BN/N/2017/0044
Date of Grant:	30 November, 2015
Annuity:	8th Year
Applicant(s) / Proprietor(s):	ASTRAZENECA AB
Title of Invention:	1-[2-(Aminomethyl)Benzyl]-2-Thioxo-1,2,3,5-Tetrahydro-4h-Pyrrolo[3,2-D]Pyrimidin-4-Ones As Inhibitors Of Myeloperoxidase



Patent No.:	BN/N/2019/0038
Date of Grant:	25 September, 2017
Annuity:	6th Year
Applicant(s) / Proprietor(s):	MERCK SHARP & DOHME CORP.
Title of Invention:	Chromane, Isochromane And Dihydroisobenzofuran Derivatives As Mglur2-Negative Allosteric Modulators, Compositions, And Their Use

Patent No.:	BN/N/2019/0048
Date of Grant:	13 October, 2017
Annuity:	6th Year
Applicant(s) / Proprietor(s):	MEDIMMUNE LIMITED
Title of Invention:	Pyrrolobenzodiazepine Conjugates

Patent No.:	BN/N/2019/0052
Date of Grant:	10 October, 2017
Annuity:	6th Year
Applicant(s) / Proprietor(s):	ARRAY BIOPHARMA INC.
Title of Invention:	Substituted Pyrazolo[1,5-A]Pyridine Compounds As Ret Kinase Inhibitors

Patent No.:	BN/N/2020/0032
Date of Grant:	17 October, 2018
Annuity:	5th Year
Applicant(s) / Proprietor(s):	INCYTE CORPORATION
Title of Invention:	Condensed Imidazole Derivatives Substituted By Tertiary Hydroxy Groups As Pi3k-Gamma Inhibitors



Date of Grant: 24 November, 2010
Annuity: 13th Year
Applicant(s) / Proprietor(s): MEDIMMUNE LIMITED
Title of Invention: Targeted Binding Agents Against B7-H1

Patent No.: RE/R/2012/0029
Date of Grant: 30 November, 2009
Annuity: 14th Year
Applicant(s) / Proprietor(s): PEAK WELL SYSTEMS PTY LTD
Title of Invention: A Retrievable Downhole Tool And Running Tool

Patent No.: RE/R/2014/0004
Date of Grant: 10 September, 2007
Annuity: 16th Year
Applicant(s) / Proprietor(s): PEAK WELL SYSTEMS PTY LTD
Title of Invention: Plant Cultivation System

Patent No.: RE/R/2014/0005
Date of Grant: 06 October, 2003
Annuity: 20th Year
Applicant(s) / Proprietor(s): TAKEDA PHARMACEUTICAL COMPANY LIMITED
Title of Invention: Solid Preparation

Patent No.: RE/R/2014/0067
Date of Grant: 20 November, 2013
Annuity: 10th Year



Applicant(s) / Proprietor(s): ASTRAZENECA AB
Title of Invention: Pyrimidine Sulphonamide Derivatives As Chemokine Receptor Modulators

Patent No.: RE/R/2016/0004
Date of Grant: 15 October, 2015
Annuity: 8th Year

Applicant(s) / Proprietor(s): PFIZER INC
Title of Invention: Dioxa-Bicyclo[3.2.1]Octane-2,3,4-Triol Derivatives

Patent No.: RE/R/2016/0017
Date of Grant: 29 September, 2011
Annuity: 12th Year

Applicant(s) / Proprietor(s): ASTRAZENECA AB
NEKTAR THERAPEUTICS

Title of Invention: Crystalline Naloxol-Peg Conjugate

Patent No.: RE/R/2016/0040
Date of Grant: 16 September, 2015
Annuity: 8th Year

Applicant(s) / Proprietor(s): ACCELERON PHARMA INC.

Title of Invention: Activin-Actrii Antagonists And Uses For Increasing Red Blood Cell Levels

Patent No.: RE/R/2017/0050
Date of Grant: 14 October, 2016
Annuity: 7th Year



Applicant(s) / Proprietor(s): GENENTECH, INC.
Title of Invention: Composition Comprising Antibody That Binds To Domain II Of Her2 And Acidic Variants Thereof

Patent No.: RE/R/2017/0056
Date of Grant: 31 October, 2016
Annuity: 7th Year
Applicant(s) / Proprietor(s): IMMUNOGEN, INC.
Title of Invention: Cross-Linkers And Their Uses

Patent No.: RE/R/2017/0058
Date of Grant: 15 November, 2016
Annuity: 7th Year
Applicant(s) / Proprietor(s): PETROLIAM NASIONAL BERHAD (PETRONAS)
Title of Invention: Water Curable Resin Formulations

Patent No.: RE/R/2018/0015
Date of Grant: 13 October, 2017
Annuity: 6th Year
Applicant(s) / Proprietor(s): THE EUROPEAN UNION, REPRESENTED BY THE EUROPEAN COMMISSION
Title of Invention: Tsunami Warning System And Method For Providing Tsunami Warnings

Patent No.: RE/R/2018/0033
Date of Grant: 08 September, 2017



Annuity:	6th Year
Applicant(s) / Proprietor(s):	ABBVIE DEUTSCHLAND GMBH & CO KG ABBVIE INC.
Title of Invention:	Monoclonal Antibodies And Uses Thereof
<hr/>	
Patent No.:	RE/R/2018/0034
Date of Grant:	13 October, 2017
Annuity:	6th Year
Applicant(s) / Proprietor(s):	TENSA ENGINEERING SDN. BHD.
Title of Invention:	Apparatus And Method For Manufacturing A Spiral Tank
<hr/>	
Patent No.:	RP/R/2004/0001
Date of Grant:	10 September, 2003
Annuity:	20th Year
Applicant(s) / Proprietor(s):	MERCK CANADA INC.
Title of Invention:	Substituted Pyridines As Selective Cyclooxygenase-2 Inhibitors
<hr/>	
Patent No.:	RP/R/2007/0060
Date of Grant:	12 September, 2007
Annuity:	16th Year
Applicant(s) / Proprietor(s):	MERCK SHARP & DOHME CORP.
Title of Invention:	Phosphoric Acid Salt Of A Dipeptidyl Peptidase-Iv Inhibitor



REGISTRAR OF PATENT

BRUNEI DARUSSALAM

PATENTS RULES [S 11/2013]

PATENT GRANTED UNDER SECTION 30

Application No.:	BN/N/2014/0005
Date of Grant:	16 February, 2015
Applicant(s) / Proprietor(s):	EINNOVATIONS HOLDINGS PTE LTD
Title of Invention:	System And Method For Activating A Mobile Device To Initiate A Communication

Application No.:	BN/N/2014/0073
Date of Grant:	31 December, 2015
Applicant(s) / Proprietor(s):	UNIVERSITI PUTRA MALAYSIA
Title of Invention:	Plastic Made Gasing Top

Application No.:	BN/N/2014/0036
Date of Grant:	19 March, 2018
Applicant(s) / Proprietor(s):	UNIVERSITI BRUNEI DARUSSALAM
Title of Invention:	Real Time Biofeedback Mechanism And Data Presentation For Knee Injury Rehabilitation Monitoring And A Soft Real Time Intelligent System Thereof

Application No.:	BN/N/2014/0037
Date of Grant:	19 March, 2018
Applicant(s) / Proprietor(s):	UNIVERSITI BRUNEI DARUSSALAM
Title of Invention:	Synthetic Fusion Gene And Its Use Thereof

Application No.:	BN/N/2014/0039
-------------------------	-----------------------



Date of Grant: 24 August, 2022
Applicant(s) / Proprietor(s): TOTAL SA
Title of Invention: A Floating Offshore Facility And A Method For Drilling A Well

Application No.: BN/N/2014/0067
Date of Grant: 06 December, 2018
Applicant(s) / Proprietor(s): CHANG, HUEI MENG
Title of Invention: Methods And Apparatuses For Water Purification

Application No.: BN/N/2014/0094
Date of Grant: 11 April, 2019
Applicant(s) / Proprietor(s): DIALOG CONSTRUCTION SDN BHD
Title of Invention: A Bulk Storage Container; And Bulk Storage Container And Bulk Material Handling Assembly Therewith

Application No.: BN/N/2016/0003
Date of Grant: 20 December, 2016
Applicant(s) / Proprietor(s): CHIKKA PTE LTD
Title of Invention: Data Bandwidth Management System And Method

Application No.: BN/N/2016/0038
Date of Grant: 28 June, 2022
Applicant(s) / Proprietor(s): CRYSTAL LAGOONS (CURACAO) B.V.
Title of Invention: Floating Lake System And Methods Of Treating Water Within The Floating Lake



Application No.: BN/N/2016/0048
Date of Grant: 24 December, 2018
Applicant(s) / Proprietor(s): ASTRAZENECA AB
Title of Invention: Pharmaceutical Compositions Comprising Azd9291

Application No.: BN/N/2017/0052
Date of Grant: 18 February, 2020
Applicant(s) / Proprietor(s): ELI LILLY AND COMPANY
Title of Invention: Antibodies To Tau And Uses Thereof

Application No.: BN/N/2019/0089
Date of Grant: 06 June, 2022
Applicant(s) / Proprietor(s): ELI LILLY AND COMPANY
Title of Invention: N-[4-Fluoro-5-[[[(2s,4s)-2-Methyl-4-[(5-Methyl-1,2,4-Oxadiazol-3-Yl)Methoxy]-1-Piperidyl]Methyl]Thiazol-2-Yl]Acetamide As Oga Inhibitor
(31) Us62/451,137

Application No.: BN/N/2019/0104
Date of Grant: 07 June, 2022
Applicant(s) / Proprietor(s): QUALITY INTERVENTION TECHNOLOGY AS
Title of Invention: Well Access Tool

Application No.: BN/N/2020/0024
Date of Grant: 06 June, 2022
Applicant(s) / Proprietor(s): NKMAX CO., LTD.
Title of Invention: Method Of Producing Natural Killer Cells And Composition For Treating Cancer



Application No.:	BN/N/2020/0032
Date of Grant:	03 August, 2022
Applicant(s) / Proprietor(s):	INCYTE CORPORATION
Title of Invention:	Condensed Imidazole Derivatives Substituted By Tertiary Hydroxy Groups As Pi3k-Gamma Inhibitors

Application No.:	BN/N/2020/0115
Date of Grant:	28 July, 2022
Applicant(s) / Proprietor(s):	AMGEN INC.
Title of Invention:	Method Of Treating Or Ameliorating Metabolic Disorders Using Binding Proteins For Gastric Inhibitory Peptide Receptor (Gipr) In Combination With Glp-1 Agonists

Application No.:	BN/N/2021/0009
Date of Grant:	27 June, 2022
Applicant(s) / Proprietor(s):	VINDA PAPER (CHINA) COMPANY LTD.
Title of Invention:	Paper Towel And Method For Manufacturing The Same

Application No.:	BN/N/2021/0050
Date of Grant:	09 June, 2022
Applicant(s) / Proprietor(s):	CRYSTAL LAGOONS TECHNOLOGIES, INC.
Title of Invention:	Construction Method For Creating A Restricted Access Swimming Lagoon With Beaches At A Retail Site

Application No.:	BN/N/2021/0051
Date of Grant:	09 June, 2022
Applicant(s) / Proprietor(s):	CRYSTAL LAGOONS TECHNOLOGIES, INC.
Title of Invention:	Transformation And Construction Method For Creating A Tropical Style Swimming Lagoon At The Infield Of Racing And/Or Activity Circuits



Application No.:	BN/N/2021/0052
Date of Grant:	11 April, 2022
Applicant(s) / Proprietor(s):	CRYSTAL LAGOONS TECHNOLOGIES, INC.
Title of Invention:	Construction Method For Creating A Tropical Style Swimming Lagoon With Beaches Within Vacant Or Abandoned Sites
<hr/>	<hr/>
Application No.:	BN/N/2021/0053
Date of Grant:	07 June, 2022
Applicant(s) / Proprietor(s):	CRYSTAL LAGOONS TECHNOLOGIES, INC.
Title of Invention:	Urban Performance Venue For The Provision Of Entertainment To An Audience In A Beach Themed Setting
<hr/>	<hr/>
Application No.:	BN/N/2021/0071
Date of Grant:	14 July, 2022
Applicant(s) / Proprietor(s):	GRABTAXI HOLDINGS PTE. LTD.
Title of Invention:	Transportation Method And Apparatus
<hr/>	<hr/>
Application No.:	BN/N/2021/0072
Date of Grant:	03 August, 2022
Applicant(s) / Proprietor(s):	GRABTAXI HOLDINGS PTE. LTD.
Title of Invention:	Automatically Determining Optimal Transport Service Locations For Points Of Interest From Noisy Multimodal Data
<hr/>	<hr/>
Application No.:	BN/N/2021/0079
Date of Grant:	12 May, 2022
Applicant(s) / Proprietor(s):	CONTROL CUTTER AS



Title of Invention: Enhanced Method For Cutting Pipes On A Drill Floor And Tool Therefor

Application No.: BN/N/2021/0086

Date of Grant: 16 August, 2022

Applicant(s) / Proprietor(s): ASTRAZENECA AB

Title of Invention: Estrogen Receptor Degrading Protacs

Application No.: BN/N/2021/0089

Date of Grant: 22 September, 2022

Applicant(s) / Proprietor(s): VOLTA PTY LTD

Title of Invention: Supercapacitor

Application No.: BN/N/2021/0100

Date of Grant: 19 July, 2022

Applicant(s) / Proprietor(s): ITERCHIMICA S.P.A.

Title of Invention: Process For The Production Of An Additive For Bituminous Conglomerates With High Mechanical Performances

Application No.: BN/N/2022/0083

Date of Grant: 29 August, 2022

Applicant(s) / Proprietor(s): HALLIBURTON ENERGY SERVICES, INC.

Title of Invention: Completion Systems And Methods 5 To Perform Completion Operations

Application No.: BN/N/2022/0084

Date of Grant: 29 August, 2022

Applicant(s) / Proprietor(s): HALLIBURTON ENERGY SERVICES, INC.



Title of Invention: Completion Systems And Methods To Perform Completion Operations



REGISTRAR OF PATENT

BRUNEI DARUSSALAM

PATENTS RULES [S 11/2013]

RECORDAL OF ASSIGNMENT

(The name in *italic* is the previous proprietor's name)

Application No.: BN/N/2015/0108

Applicant(s) / Proprietor(s): Sumitomo Pharma Co., Ltd. of 6-8, Doshomachi 2-chome, Chuo-ku, Osaka-shi, Osaka 541-0045, Japan
Sumitomo Dainippon Pharma Co., Ltd. of 6-8, Dosho-machi 2-chome, Chuo-Ku, Osaka-shi, Osaka 5418524, Japan

Title of Invention: Wt1-Antigen Peptide Conjugate Vaccine

Agent and/ or Address for Service :

Messrs. MARKS&CLERK SINGAPORE LLP c/o AIP Law of Unit Nos. 404A-410A 4th Floor, Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam
